WO2007021803A1 - Compounds for the treatment of inflammatory disorders - Google Patents

Compounds for the treatment of inflammatory disorders Download PDF

Info

Publication number
WO2007021803A1
WO2007021803A1 PCT/US2006/031151 US2006031151W WO2007021803A1 WO 2007021803 A1 WO2007021803 A1 WO 2007021803A1 US 2006031151 W US2006031151 W US 2006031151W WO 2007021803 A1 WO2007021803 A1 WO 2007021803A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
alkyl
heteroaryl
aryl
independently selected
Prior art date
Application number
PCT/US2006/031151
Other languages
French (fr)
Other versions
WO2007021803A8 (en
Inventor
Zhaoning Zhu
Robet D. Mazzola
Wensheng Yu
Joseph A. Kozlowski
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Priority to EP06789659A priority Critical patent/EP1948638B1/en
Priority to AT06789659T priority patent/ATE518853T1/en
Priority to MX2008002073A priority patent/MX2008002073A/en
Priority to CA002618679A priority patent/CA2618679A1/en
Priority to JP2008526185A priority patent/JP2009504666A/en
Publication of WO2007021803A1 publication Critical patent/WO2007021803A1/en
Publication of WO2007021803A8 publication Critical patent/WO2007021803A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • This invention relates to hydroxamic or carboxylic acid functional compounds that can inhibit the production of tumor necrosis factor alpha (TNF- ⁇ ), pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.
  • TNF- ⁇ tumor necrosis factor alpha
  • TNF- ⁇ Tumor necrosis factor alpha
  • RA rheumatoid arthritis
  • sepsis rheumatoid arthritis
  • Inhibition of TNF- ⁇ production has been shown to be beneficial in many preclinical models of inflammatory disease, making inhibition of TNF- ⁇ production or signaling an appealing target for the development of novel anti-inflammatory drugs.
  • Tumor necrosis factor alpha is a cell-associated cytokine that is processed from a 26 kd precursor form to a 17 kd active form. See Black R.A. "Tumor necrosis factor-alpha converting enzyme” lnt J Biochem Cell Biol. 2002 Jan;34(1):1-5 and Moss ML, White JM, Lambert MH, Andrews RC 1 TACE and other ADAM proteases as targets for drug discovery" Drug Discov Today. 2001 Apr 1 ;6(8):417-426, each of which is incorporated by reference herein.
  • TNF- ⁇ has been shown to be a primary mediator in humans and animals of inflammation, fever and acute phase responses, similar to those observed during acute infection and shock. Excess TNF- ⁇ has been shown to be lethal. Blocking the effects of TNF- ⁇ with specific antibodies can be beneficial in a variety of conditions, including autoimmune diseases such as rheumatoid arthritis (Feldman et al, Lancet, (1994) 344, 1105), non-insulin dependent diabetes mellitus (Lohmander L. S. et al., Arthritis Rheum. 36 (1993) 1214-22) and Crohn's disease (Macdonald T. et al., Clin. Exp. Immunol. 81 (1990) 301 ).
  • autoimmune diseases such as rheumatoid arthritis (Feldman et al, Lancet, (1994) 344, 1105), non-insulin dependent diabetes mellitus (Lohmander L. S. et al., Arthriti
  • Metalloproteinases are important in the uncontrolled breakdown of connective tissue, including proteoglycan and collagen, leading to resorption of the extracellular matrix. This is a feature of many pathological conditions, such as rheumatoid and osteo- arthritis, corneal, epidermal or gastric ulceration; tumor metastasis or invasion; periodontal disease and bone disease. Normally these catabolic enzymes are tightly regulated at the level of their synthesis as well as at their level of extracellular activity through the action of specific inhibitors, such as alpha-2-macroglobulins and TIMP (tissue inhibitor of metalloproteinase), which form inactive complexes with the MP's.
  • specific inhibitors such as alpha-2-macroglobulins and TIMP (tissue inhibitor of metalloproteinase), which form inactive complexes with the MP's.
  • Osteo- and rheumatoid arthritis are destructive diseases of articular cartilage characterized by localized erosion of the cartilage surface. Findings have shown that articular cartilage from the femoral heads of patients with OA, for example, had a reduced incorporation of radiolabeled sulfate over controls, suggesting that there must be an enhanced rate of cartilage degradation in OA (Mankin et al. J. Bone Joint Surg. 52A (1970) 424-434).
  • aggrecanase (a newly identified metalloproteinase enzymatic activity) has been identified that provides the specific cleavage product of proteoglycan, found in RA and OA patients (Lohmander L. S. et al. Arthritis Rheum. 36, 1993, 1214-22).
  • MP metalloproteinases
  • MMP matrix metalloproteinase
  • TACE family of metalloproteinases
  • other MP's are capable of converting TNF- ⁇ from its inactive to active form. Since excessive TNF- ⁇ production has been noted in several disease conditions also characterized by MMP-mediated tissue degradation, compounds which inhibit both MMPs and TNF- ⁇ production may also have a particular advantage in diseases where both mechanisms are involved.
  • U.S. Patent 6,838,466 refers to hydroxamic or carboxylic acid functional compounds that can inhibit the production of tumor necrosis factor alpha (TNF- ⁇ ).
  • WO03/053940 refers to barbituric acid derivatives useful as TNF- ⁇ converting enzyme (TACE) and matrix metalloproteinase (MMP) inhibitors.
  • W095/09841 describes compounds that are hydroxamic acid derivatives and are inhibitors of cytokine production.
  • European Patent Application Publication No. 574,758 A1 discloses hydroxamic acid derivatives as collagenase inhibitors.
  • GB 2 268 934 A and WO 94/24140 claim hydroxamate inhibitors of MMPs as inhibitors of TNF- ⁇ production.
  • TNF- ⁇ convertase which can be useful as anti-inflammatory compounds and cartilage protecting therapeutics.
  • the inhibition of TNF- ⁇ convertase and other metalloproteinases can prevent the degradation of cartilage by these enzymes, thereby alleviating the pathological conditions of osteo- and rheumatoid arthritis.
  • the present invention provides a novel class of compounds as inhibitors of TACE, the production of TNF- ⁇ , MMPs, ADAMs or any combination thereof, methods of preparing such compounds, pharmaceutical compositions comprising one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition or amelioration of one or more diseases associated with TACE, TNF- ⁇ , MMPs, ADAMs or any combination thereof using such compounds or pharmaceutical compositions.
  • the present application discloses a compound having the general structure shown in Formula (I):
  • M together with the two carbon atoms to which it is shown attached in formula (I) is 4-7 membered hetereocyclyl or heterocyclenyl comprising 0-3 carbonyl groups,
  • 4-7 membered hetereocyclyl or heterocycienyl can, in addition to the four substituents V, R 2 , T, and -(W) n -X-U-R 1 as set forth in formula (I), be further optionally substituted with R 21 ;
  • T is selected from the group consisting of H, alkyl, R 21 -substituted alkyl, cycloalkyl, aryl, heteroaryl, hetereocyclyl, arylalkyl, heteroarylalkyl, -OR 3 , -C(O)R 4 , -C(O)OR 3 ,
  • each of the cycloalkyl, aryl, heteroaryl, hetereocyclyl, arylalkyl and heteroarylalkyl groups of T is unsubstituted or optionally independently substituted with one to six R 20 moieties which can be the same or different, each R 20 moiety being independently selected from the group of R 20 moieties below;
  • V is selected from the group consisting of alkyl, R 21 -substituted alkyl, cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl, heteroaryl, -OR 3 , -C(O)R 4 , -(CR 23 R 24 ) n i C(O)OR 3 , -C(O)NR 24 R 25 , -(CR 23 R 24 ) n1 C(O)NR 25 OR 3 , -C(O)SR 3 , -C(R 23 )(R 24 )SH, -NR 24 R 25 , -NR 25 C(O)R 4 , -NR 25 C(O)OR 3 , -NR 25 C(O)NR 24 R 25 , -NR 25 C(O)NR 24 OR 3 , -SR 3 , -S(O) x NR 24 R 25 , -S(O) x NR 25 OR 3
  • W is selected from the group consisting of
  • X is selected from the group consisting of alkyl, cylcloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl, heteroaryl and -C ⁇ C- ; wherein each of the alkyl, cylcloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl groups of X is unsubstituted or optionally independently substituted with one to four selected R 20 moieties which can be the same or different, each R 20 moiety being independently selected from the group of R 20 moieties below,
  • U is selected from the group consisting of a covalent bond
  • Q is selected from the group consisting of -S(O)-, -S(O) 2 -, -C(O)-, and - C(O)NR 4 -;
  • Y is selected from the group consisting of -O-, -S(O) x -, -N(Z)-, -N(R 4 )(Z); - C(O)-, -OC(O)-, -C(O)N(R 24 )-, -N(R 24 )C(O)N(R 25 )-, -N(R 24 )S(O)-, -N(R 24 )S(O) 2 -, -S(O)N(R 24 )-, and -S(O) 2 N(R 24 )-;
  • Z is selected from the group consisting of -R 3 , -C(O)R 3 , -S(O) x R 3 and -C(O)NR 3 R 4 ;
  • p is 1 to 4;
  • q is 1 to 4;
  • t
  • R 26 is selected from the group consisting of H, alkyl, cycloalkyl, aryl, and heteroaryl;
  • the present invention discloses a compound represented by the structural formula (II):
  • L is aryl or heteroaryl
  • V is selected from the group consisting of alkyl, R 21 -substituted alkyl, cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl, heteroaryl, -OR 3 , -C(O)R 4 , -(CR 23 R 24 )ni C(O)OR 3 , -C(O)NR 24 R 25 ,
  • R 31 and R 32 together with the N to which R 31 is attached and the C to which R 31 is attached, form a 5-membered ring which is unsubstituted or optionally independently substituted with a hydroxyl group.
  • the present invention provides a compound of formula (III) Formula HI or a pharmaceutically acceptable salt, solvate or ester of said compound, wherein:
  • L is aryl or heteroaryl
  • T is selected from the group consisting of H, alkyl, R 21 -substituted alkyl, cycloalkyl, aryl, heteroaryl, hetereocyclyl, arylalkyl, heteroarylalkyl, -OR 3 , -C(O)R 4 , -C(O)OR 3 , -C(O)NR 24 R 25 , -C(O)NR 24 OR 3 , -C(O)SR 3 , -NR 24 R 25 , -NR 25 C(O)R 4 , - NR 25 C(O)OR 3 , -NR 25 C(O)NR 24 R 25 , -NR 25 C(O)NR 24 OR 3 , -SR 3 , -N(R 24 JS(O) 2 R 25 , - S(O) x NR 24 R 25 , -S(O) x NR 25 OR 3 , -CN, -P(O)(R 24 )
  • V is selected from the group consisting of alkyl, R 21 -substituted alkyl, cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl, heteroaryl, -OR 3 , -C(O)R 4 , -(CR 23 R 24 ) n iC(O)OR 3 , -C(O)NR 24 R 25 ,
  • R 31 and R 32 together with the N to which R 31 is attached and the C to which R 31 is attached, form a 5-membered ring which is unsubstituted or optionally independently substituted with a hydroxyl group.
  • the compounds of Formula I, Il or III can be useful as inhibitors of and can be useful in the treatment and prevention of diseases associated with TACE, TNF- a, MMPs, ADAMs or any combination thereof.
  • the present invention provides a novel class of inhibitors of MMP and TNF- ⁇ convertase, pharmaceutical compositions containing one or more of the compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention or amelioration of one or more of the symptoms of inflammation.
  • the present invention provides compounds which are represented by structural Formula (I), (II) or (III) above or a pharmaceutically acceptable salt, solvate or ester of any of Formula (I), (II) or (III), wherein the various moieties are as described above.
  • n 1
  • M in the compound of formula (I), represents a 4-5 membered hetereocyclyl or heterocyclenyl comprising 0-1 carbonyl groups, 0-1 double bonds, and 1 heteroatom selected from O, N, and S, wherein said 4-5 membered hetereocyclyl can, in addition to the four substituents V, R 2 , T, and - (W) n -X-U-R 1 as set forth in formula (I), be further optionally substituted R 21 ; T is selected from H and -C(O)OR 3 ;
  • V is -C(O)R 4 or -C(O)NR 24 R 25
  • W is -(C(R 3 )(R 4 )) n2 -;
  • X is aryl, wherein said aryl is unsubstituted or optionally independently substituted with one to four selected R 20 moieties which can be the same or different, each R 20 moiety being independently selected from the group of R 20 moieties below,
  • U is -Y-(C(R 3 )(R 4 )) q -;
  • Y is -O-; n is 0 to 2; n2 is 1 to 2; q is 1 to 4; x is 0 to 2;
  • W is -CH 2 - in formula (I).
  • U is -0-CH 2 - in formula (I).
  • U is -OCH(CO 2 CH 3 )- in formula (I).
  • T is H in formula (I).
  • T is -C(O)OCH 2 CH 3 in formula (I).
  • V is -C(O) 2 H in formula (I).
  • V is -C(O)NHOH in formula (I).
  • M togetherwith the two carbon atoms to which it is shown attached in formula (I), represents a 5 membered hetereocyclyl comprising 1 heteroatom selected from O, N, and S, wherein said 5 membered hetereocyclyl is only substituted with the four substituents V, R 2 , T, and -(W) n -X-U-R 1 as set forth in formula (I).
  • M together with the two carbon atoms to which it is shown attached in formula (I), represents a 4 membered hetereocyclyl comprising 1 carbonyl group and 1 heteroatom selected from O, N, and S, wherein said 4 membered hetereocyclyl is only substituted with the four substituents V, R 2 , T, and -(W) n -X-U-R 1 as set forth in formula (I).
  • T is -C(O)OR 3 , wherein R 3 is an alkyl.
  • R 1 is a heteroaryl with 1 heteroatom selected from S, O and N, wherein said heteroaryl is substituted with a phenyl moiety.
  • R 1 is a heteroaryl with 1 heteroatom selected from S, O and N, wherein said heteroaryl is substituted with a phenyl moiety, and wherein said heteroaryl is quinolinyl.
  • R 1 is
  • V is -(CR 23 R 24 ) n1 C(O)N R 25 OR 3 wherein n1 is O, and both R 3 and R 25 are H.
  • L is aryl; in another embodiment said aryl is phenyl.
  • G 2 is H.
  • T is H.
  • R 2 and R 5 are both hydrogen.
  • one of R 3 and R 4 is H, and the other is -C(O)OR 6 .
  • both R 3 and R 4 are H.
  • R 1 is a heteroaryl with 1 heteroatom selected from S, O and N, wherein said heteroaryl is substituted with a phenyl moiety.
  • R 1 is a heteroaryl with 1 heteroatom selected from S, O and N, wherein said heteroaryl is substituted with a phenyl moiety, and wherein said heteroaryl is quinolinyl.
  • R 1 is
  • V is selected from the group consisting of -(CR 23 R 24 ) n iC(O)OR 3 and -(CR 23 R 24 ) n1 C(O)NR 25 OR 3 wherein n1 is 0 and both R 3 and R 25 are H.
  • L is aryl; in another embodiment said aryl is phenyl.
  • the compound of formula (I) is selected from the group consisting of:
  • Patient includes both human and animals.
  • “Mammal” means humans and other mammalian animals.
  • Alkyl means an aliphatic hydrocarbon group which may be straight or branched and comprising about 1 to about 20 carbon atoms in the chain. Preferred alkyl groups contain about 1 to about 12 carbon atoms in the chain. More preferred alkyl groups contain about 1 to about 6 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkyl chain. "Lower alkyl” means a group having about 1 to about 6 carbon atoms in the chain which may be straight or branched.
  • Alkyl may be unsubstituted or optionally substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, aryl, cycloalkyl, cyano, hydroxy, alkoxy, alkylthio, amino, -NH(alkyl), -NH(cycloalkyl), -N(alkyl) 2 , carboxy and - C(O)O-alkyl.
  • suitable alkyl groups include methyl, ethyl, n-propyl, isopropyl and t-butyl.
  • R 21 - substituted alkyl means that the alkyl group can be substituted by one or more R 21 substituents that may be the same or different, each substituent being independently selected from the group consisting of R 21 substituents listed above.
  • R 21 substituents that may be the same or different, each substituent being independently selected from the group consisting of R 21 substituents listed above.
  • Each of the aryl, halo-substituted aryl, heteroaryl, cycloalkyl and heterocycloalkyl groups of R 21 can be unsubstituted or independently substituted with one to four independently selected R 23 moieties which can be the same or different, each R 23 moiety being independently selected from the group of R 23 moieties above.
  • R 22 - substituted alkyl means that the alkyl group can be substituted by one or more R 22 substituents that may be the same or different, each substituent being independently selected from the group consisting of R 22 substituents listed above.
  • R 52 - substituted alkyl means that the alkyl group can be substituted by one or more R 52 substituents which may be the same or different, each substituent being independently selected from the group consisting of R 21 substituents listed above.
  • Alkenyl means an aliphatic hydrocarbon group containing at least one carbon-carbon double bond and which may be straight or branched and comprising about 2 to about 15 carbon atoms in the chain.
  • Preferred alkenyl groups have about 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 6 carbon atoms in the chain.
  • Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkenyl chain.
  • “Lower alkenyl” means about 2 to about 6 carbon atoms in the chain which may be straight or branched.
  • alkenyl may be unsubstituted or optionally substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of halo, alkyl. aryl, cycloalkyl, cyano, alkoxy and -S(alkyl).
  • suitable alkenyl groups include ethenyl, propenyl, n-butenyl, 3-methylbut-2-enyl, n- pentenyl, octenyl and decenyl.
  • Alkylene means a difunctional group obtained by removal of a hydrogen atom from an alkyl group that is defined above.
  • alkylene include methylene, ethylene and propylene.
  • Alkynyl means an aliphatic hydrocarbon group containing at least one carbon-carbon triple bond and which may be straight or branched and comprising about 2 to about 15 carbon atoms in the chain.
  • Preferred alkynyl groups have about 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 4 carbon atoms in the chain.
  • Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkynyl chain.
  • “Lower alkynyl” means about 2 to about 6 carbon atoms in the chain which may be straight or branched.
  • alkynyl groups include ethynyl, propynyl, 2-butynyl and 3-methylbutynyl.
  • Alkynyl may be unsubstituted or optionally substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of alkyl, aryl and cycloalkyl.
  • Aryl means an aromatic monocyclic or multicyclic ring system comprising about 6 to about 14 carbon atoms, preferably about 6 to about 10 carbon atoms.
  • the aryl group can be optionally substituted with one or more "ring system substituents" which may be the same or different, and are as defined herein.
  • suitable aryl groups include phenyl and naphthyl.
  • Heteroaryl means an aromatic monocyclic or multicyclic ring system comprising about 5 to about 14 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the ring atoms is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination. Preferred heteroaryls contain about 5 to about 6 ring atoms.
  • the "heteroaryl” can be optionally substituted by one or more "ring system substituents" which may be the same or different, and are as defined herein.
  • the prefix aza, oxa or thia before the heteroaryl root name means that at least a nitrogen, oxygen or sulfur atom respectively, is present as a ring atom.
  • a nitrogen atom of a heteroaryl can be optionally oxidized to the corresponding N-oxide.
  • suitable heteroaryls include pyridyl, pyrazinyl, furanyl, thienyl, pyrimidinyl, pyridone (including N-substituted pyridones), isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, pyrazolyl, furazanyl, pyrrolyl, pyrazolyl, triazolyl, 1 ,2,4-thiadiazolyl, pyrazinyl, pyridazinyl, quinoxalinyl, phthalazinyl, oxindolyl, imidazo[1 ,2-a]pyridinyl, imidazo[2,1-b]thiazolyl, benzofurazanyl, indolyl, azaindolyl, benzimidazolyl, be
  • Aralkyl or “arylalkyl” means an aryl-alkyl- group in which the aryl and alkyl are as previously described. Preferred aralkyls comprise a lower alkyl group. Non- limiting examples of suitable aralkyl groups include benzyl, 2-phenethyl and naphthalenylmethyl. The bond to the parent moiety is through the alkyl.
  • Alkylaryl means an alkyl-aryl- group in which the alkyl and aryl are as previously described. Preferred alkylaryls comprise a lower alkyl group. Non- limiting example of a suitable alkylaryl group is tolyl. The bond to the parent moiety is through the aryl.
  • Cycloalkyl means a non-aromatic mono- or multicyclic ring system comprising about 3 to about 10 carbon atoms, preferably about 5 to about 10 carbon atoms. Preferred cycloalkyl rings contain about 5 to about 7 ring atoms.
  • the cycloalkyl can be optionally substituted with one or more "ring system substituents" which may be the same or different, and are as defined above.
  • suitable monocyclic cycloalkyls include cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl and the like.
  • suitable multicyclic cycloalkyls include 1-decalinyl, norbornyl, adamantyl and the like.
  • Cycloalkylalkyl means a cycloalkyl moiety as defined above linked via an alkyl moiety (defined above) to a parent core.
  • suitable cycloalkylalkyls include cyclohexyl methyl, adamantylmethyl and the like.
  • Cycloalkenyl means a non-aromatic mono or multicyclic ring system comprising about 3 to about 10 carbon atoms, preferably about 5 to about 10 carbon atoms which contains at least one carbon-carbon double bond. Preferred cycloalkenyl rings contain about 5 to about 7 ring atoms.
  • the cycloalkenyl can be optionally substituted with one or more "ring system substituents" which may be the same or different, and are as defined above.
  • suitable monocyclic cycloalkenyls include cyclopentenyl, cyclohexenyl, cyclohepta-1 ,3- dienyl, and the like.
  • Non-limiting example of a suitable multicyclic cycloalkenyl is norbomylenyl.
  • Cycloalkenylalkyl means a cycloalkenyl moiety as defined above linked via an alkyl moiety (defined above) to a parent core.
  • suitable cycloalkenylalkyls include cyclopentenylmethyl, cyclohexenylmethyl and the like.
  • Halogen means fluorine, chlorine, bromine, or iodine. Preferred are fluorine, chlorine and bromine.
  • Ring system substituent means a substituent attached to an aromatic or non-aromatic ring system which, for example, replaces an available hydrogen on the ring system.
  • Ring system substituents may be the same or different, each being independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, alkylaryl, heteroaralkyl, heteroarylalkenyl, heteroarylalkynyl, alkylheteroaryl, hydroxy, hydroxyalkyl, alkoxy, aryloxy, aralkoxy, acyl, aroyl, halo, nitro, cyano, carboxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, alkylthio, arylthio, heteroarylthio, aralkylthio
  • Ring system substituent may also mean a single moiety which simultaneously replaces two available hydrogens on two adjacent carbon atoms (one H on each carbon) on a ring system.
  • Examples of such moiety are methylene dioxy, ethylenedioxy, -C(CHs) 2 - and the like which form moieties such as, for example:
  • Heteroarylalkyl means a heteroaryl moiety as defined above linked via an alkyl moiety (defined above) to a parent core.
  • suitable heteroaryls include 2-pyridinylmethyl, quinolinylmethyl and the like.
  • Heterocyclyl means a non-aromatic saturated monocyclic or multicyclic ring system comprising about 3 to about 10 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the atoms in the ring system is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination. There are no adjacent oxygen and/or sulfur atoms present in the ring system.
  • Preferred heterocyclyls contain about 5 to about 6 ring atoms.
  • the prefix aza, oxa or thia before the heterocyclyl root name means that at least a nitrogen, oxygen or sulfur atom respectively is present as a ring atom.
  • Any -NH in a heterocyclyl ring may exist protected such as, for example, as an -N(Boc), - N(CBz), -N(Tos) group and the like; such protections are also considered part of this invention.
  • the heterocyclyl can be optionally substituted by one or more "ring system substituents" which may be the same or different, and are as defined herein.
  • the nitrogen or sulfur atom of the heterocyclyl can be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide.
  • heterocyclyl rings include piperidyl, pyrrolidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, 1 ,4-dioxanyl, tetrahydrofuranyl, tetrahydrothiophenyl, lactam, lactone, and the like.
  • Heterocyclyl may also include a single moiety (e.g., carbonyl) which simultaneously replaces two available hydrogens on the same carbon atom on a ring system.
  • An example of such a heterocyclyl is pyrrolidone:
  • Heterocyclylalkyl means a heterocyclyl moiety as defined above linked via an alkyl moiety (defined above) to a parent core.
  • suitable heterocyclylalkyls include piperidinylmethyl, piperazinylmethyl and the like.
  • Heterocyclenyl means a non-aromatic monocyclic or multicyclic ring system comprising about 3 to about 10 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the atoms in the ring system is an element other than carbon, for example nitrogen, oxygen or sulfur atom, alone or in combination, and which contains at least one carbon-carbon double bond or carbon-nitrogen double bond.
  • heterocyclenyl rings contain about 5 to about 6 ring atoms.
  • the prefix aza, oxa or thia before the heterocyclenyl root name means that at least a nitrogen, oxygen or sulfur atom respectively is present as a ring atom.
  • the heterocyclenyl can be optionally substituted by one or more ring system substituents, wherein "ring system substituent" is as defined above.
  • the nitrogen or sulfur atom of the heterocyclenyl can be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide.
  • Non-limiting examples of suitable heterocyclenyl groups include 1 ,2,3,4- tetrahydropyridine, 1 ,2-dihydropyridyl, 1 ,4- dihydropyridyl, 1 ,2,3,6-tetrahydropyridine, 1 ,4,5,6-tetrahydropyrimidine, 2- pyrrolinyl, 3-pyrrolinyl, 2-imidazolinyl, 2-pyrazolinyl, dihydroimidazole, dihydrooxazole, dihydrooxadiazole, dihydrothiazole, 3,4-dihydro-2H-pyran, dihydrofuranyl, fluorodihydrofuranyl, 7-oxabicyclo[2.2.1]heptenyl, dihydrothiophenyl, dihydrothiopyranyl, and the like.
  • Heterocyclenyl may also include a single moiety (e.g., carbonyl) which simultaneously replaces two available hydrogens on the same carbon atom on a ring system.
  • a heterocyclenyl is pyrrolidinone:
  • Heterocyclenylalkyl means a heterocyclenyl moiety as defined above linked via an alkyl moiety (defined above) to a parent core.
  • hetero-atom containing ring systems of this invention there are no hydroxyl groups on carbon atoms adjacent to a N, O or S, as well as there are no N or S groups on carbon adjacent to another heteroatom.
  • N, O or S there are no hydroxyl groups on carbon atoms adjacent to a N, O or S, as well as there are no N or S groups on carbon adjacent to another heteroatom.
  • Alkynylalkyl means an alkynyl-alkyl- group in which the alkynyl and alkyl are as previously described. Preferred alkynylalkyls contain a lower alkynyl and a lower alkyl group. The bond to the parent moiety is through the alkyl. Non-limiting examples of suitable alkynylalkyl groups include propargylmethyl.
  • Heteroaralkyl means a heteroaryl-alkyl- group in which the heteroaryl and alkyl are as previously described. Preferred heteroaralkyls contain a lower alkyl group. Non-limiting examples of suitable aralkyl groups include pyridylmethyl, and quinolin-3-ylmethyl. The bond to the parent moiety is through the alkyl.
  • Hydroxyalkyl means a HO-alkyl- group in which alkyl is as previously defined. Preferred hydroxyalkyls contain lower alkyl. Non-limiting examples of suitable hydroxyalkyl groups include hydroxymethyl and 2-hydroxyethyl.
  • acyl means an H-C(O)-, alkyl-C(O)- or cycloalkyl-C(O)-, group in which the various groups are as previously described.
  • the bond to the parent moiety is through the carbonyl.
  • Preferred acyls contain a lower alkyl.
  • suitable acyl groups include formyl, acetyl and propanoyl.
  • Aroyl means an aryl-C(O)- group in which the aryl group is as previously described.
  • the bond to the parent moiety is through the carbonyl.
  • suitable groups include benzoyl and 1- naphthoyl.
  • Alkoxy means an alkyl-O- group in which the alky! group is as previously described.
  • suitable alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy and n-butoxy.
  • the bond to the parent moiety is through the ether oxygen.
  • Aryloxy means an aryl-O- group in which the aryl group is as previously described.
  • suitable aryloxy groups include phenoxy and naphthoxy.
  • the bond to the parent moiety is through the ether oxygen.
  • Alkyloxy means an aralkyl-O- group in which the aralkyl group is as previously described.
  • suitable aralkyloxy groups include benzyloxy and 1 - or 2-naphthalenemethoxy.
  • the bond to the parent moiety is through the ether oxygen.
  • Alkylthio means an alkyl-S- group in which the alkyl group is as previously described.
  • suitable alkylthio groups include methylthio and ethylthio.
  • the bond to the parent moiety is through the sulfur.
  • Arylthio means an aryl-S- group in which the aryl group is as previously described.
  • suitable arylthio groups include phenylthio and naphthylthio.
  • the bond to the parent moiety is through the sulfur.
  • Alkylthio means an aralkyl-S- group in which the aralkyl group is as previously described.
  • Non-limiting example of a suitable aralkylthio group is benzylthio.
  • the bond to the parent moiety is through the sulfur.
  • Alkoxycarbonyl means an alkyl-O-CO- group.
  • suitable alkoxycarbonyl groups include methoxycarbonyl and ethoxycarbonyl.
  • the bond to the parent moiety is through the carbonyl.
  • Aryloxycarbonyl means an aryl-O-C(O)- group.
  • suitable aryloxycarbonyl groups include phenoxycarbonyl and naphthoxycarbonyl.
  • the bond to the parent moiety is through the carbonyl.
  • Alkoxycarbonyl means an aralkyl-O-C(O)- group.
  • a suitable aralkoxycarbonyl group is benzyloxycarbonyl.
  • the bond to the parent moiety is through the carbonyl.
  • Alkylsulfonyl means an alkyl-S(O 2 )- group. Preferred groups are those in which the alkyl group is lower alkyl. The bond to the parent moiety is through the sulfonyl.
  • Arylsulfonyl means an ary!-S(O 2 )- group. The bond to the parent moiety is through the sulfonyl.
  • substituted means that one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
  • stable compound' or “stable structure” is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
  • purified refers to the physical state of said compound after being isolated from a synthetic process or natural source or combination thereof.
  • purified refers to the physical state of said compound after being obtained from a purification process or processes described herein or well known to the skilled artisan, in sufficient purity to be characterizable by standard analytical techniques described herein or well known to the skilled artisan.
  • protecting groups When a functional group in a compound is termed "protected”, this means that the group is in modified form to preclude undesired side reactions at the protected site when the compound is subjected to a reaction. Suitable protecting groups will be recognized by those with ordinary skill in the art as well as by reference to standard textbooks such as, for example, T. W. Greene et al, Protective Groups in organic Synthesis (1991), Wiley, New York.
  • any variable e.g., aryl, heterocycle, R 2 , etc.
  • its definition on each occurrence is independent of its definition at every other occurrence.
  • composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
  • Prodrugs and solvates of the compounds of the invention are also contemplated herein.
  • a discussion of prodrugs is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems (1987) t4 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, (1987) Edward B. Roche, ed., American Pharmaceutical Association and Pergamon Press.
  • the term "prodrug” means a compound (e.g, a drug precursor) that is transformed in vivo to yield a compound of Formula (I), (II), or (III), or a pharmaceutically acceptable salt, hydrate or solvate of the compound.
  • the transformation may occur by various mechanisms (e.g., by metabolic or chemical processes), such as, for example, through hydrolysis in blood.
  • mechanisms e.g., by metabolic or chemical processes
  • prodrugs are provided by T. Higuchi and W. Stella, "Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.
  • a prodrug can comprise an ester formed by the replacement of the hydrogen atom of the acid group with a group such as, for example, (Ci-C ⁇ )alkyl, (C 2 -Ci 2 )alkanoyloxymethyl, 1-(alkanoyloxy)ethyl having from 4 to 9 carbon atoms, 1-methyl-1-(alkanoyloxy)-ethyl having from 5 to 10 carbon atoms, alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms, 1- (alkoxycarbonyloxy)ethyl having from 4 to 7 carbon atoms, 1-methyl-1- (alkoxycarbonyloxy)ethyl having from 5 to 8 carbon atoms, N- (alkoxycarbonyl)aminomethyl having from 3 to 9 carbon atoms, 1-(Ci-C ⁇ )alkyl, (C 2 -Ci 2 )alkanoyloxymethyl, 1-(alkanoyloxy)ethyl having from 4 to 9 carbon
  • a prodrug can be formed by the replacement of the hydrogen atom of the alcohol group with a group such as, for example, (Cr C 6 )alkanoyloxymethyl, 1-((CrC 6 )alkanoyloxy)ethyl, 1-methyl-1-((Cr C- 6 )alkanoyloxy)ethyl, (Ci-C ⁇ jalkoxycarbonyloxymethyl, N-(Cr C 6 )a!koxycarbonylaminomethyl, succinoyl, (CrC ⁇ ialkanoyi, ⁇ -amino(Cr C 4 )alkanyl, arylacyl and ⁇ -aminoacyl, or ⁇ -aminoacyl- ⁇ -aminoacyl, where each ⁇ - aminoacyl group is independently selected from the naturally occurring L-amino acids, P(O)(OH) 2 ,
  • a prodrug can be formed by the replacement of a hydrogen atom in the amine group with a group such as, for example, R-carbonyl, RO-carbonyl, NRR'- carbonyl where R and R' are each independently (CrC-io)alkyl, (C 3 -C 7 ) cycloalkyl, benzyl, or R-carbonyl is a natural ⁇ -aminoacyl or natural ⁇ -aminoacyl, — C(OH)C(O)OY 1 wherein Y 1 is H, (C r C 6 )alkyl or benzyl, — C(OY 2 )Y 3 wherein Y 2 is (C 1 -C 4 ) alkyl and Y 3 is (C 1 -C 6 )alkyl, carboxy (Ci-C ⁇ )alkyl, amino(CrC 4 )al
  • One or more compounds of the invention may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the invention embrace both solvated and unsolvated forms.
  • “Solvate” means a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. "Solvate” encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like.
  • “Hydrate” is a solvate wherein the solvent molecule is H 2 O.
  • One or more compounds of the invention may optionally be converted to a solvate.
  • Preparation of solvates is generally known.
  • M. Caira et al, J. Pharmaceutical ScL, 93(3), 601-611 (2004) describe the preparation of the solvates of the antifungal fluconazole in ethyl acetate as well as from water.
  • Similar preparations of solvates, hemisolvate, hydrates and the like are described by E. C. van Tonder et al, AAPS PharmSciTech., 5(1), article 12 (2004); and A. L. Bingham et al, Chem. Commun., 603-604 (2001).
  • a typical, non-limiting, process involves dissolving the inventive compound in desired amounts of the desired solvent (organic or water or mixtures thereof) at a higher than ambient temperature, and cooling the solution at a rate sufficient to form crystals which are then isolated by standard methods.
  • Analytical techniques such as, for example I. R. spectroscopy, show the presence of the solvent (or water) in the crystals as a solvate (or hydrate).
  • Effective amount or “therapeutically effective amount” is meant to describe an amount of compound or a composition of the present invention effective in inhibiting the above-noted diseases and thus producing the desired therapeutic, ameliorative, inhibitory or preventative effect.
  • the compounds of Formula (I), (II), or (III) can form salts which are also within the scope of this invention.
  • Reference to a compound of Formula (I), (II), or (III) herein is understood to include reference to salts thereof, unless otherwise indicated.
  • the term "salt(s)", as employed herein, denotes acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases.
  • a compound of Formula (I), (II), or (III) contains both a basic moiety, such as, but not limited to a pyridine or imidazole, and an acidic moiety, such as, but not limited to a carboxylic acid, zwitterions ("inner salts") may be formed and are included within the term “salt(s)" as used herein.
  • Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred, although other salts are also useful.
  • Salts of the compounds of the Formula (I), (II), or (III) may be formed, for example, by reacting a compound of Formula (I), (II) or (III) with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.
  • Exemplary acid addition salts include acetates, ascorbates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, fumarates, hydrochlorides, hydrobromides, hydroiodides, lactates, maleates, methanesulfonates, naphthalenesulfonates, nitrates, oxalates, phosphates, propionates, salicylates, succinates, sulfates, tartarates, thiocyanates, toluenesulfonates (also known as tosylates,) and the like.
  • Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as dicyclohexylamines, t-butyl amines, and salts with amino acids such as arginine, lysine and the like.
  • Basic nitrogen-containing groups may be quartemized with agents such as lower alkyl halides (e.g. methyl, ethyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g.
  • dimethyl, diethyl, and dibutyl sulfates dimethyl, diethyl, and dibutyl sulfates
  • long chain halides e.g. decyl, lauryl, and stearyl chlorides, bromides and iodides
  • aralkyl halides e.g. benzyl and phenethyl bromides
  • esters of the present compounds include the following groups: (1) carboxylic acid esters obtained by esterification of the hydroxy groups, in which the non-carbonyl moiety of the carboxylic acid portion of the ester grouping is selected from straight or branched chain alkyl (for example, acetyl, n-propyl, t-butyl, or n-butyl), alkoxyalkyl (for example, methoxymethyl), aralkyl (for example, benzyl), aryloxyalkyl (for example, phenoxymethyl), aryl (for example, phenyl optionally substituted with, for example, halogen, C- ⁇ _ 4 alkyl, or Ci- 4 alkoxy or amino); (2) sulfonate esters, such as alkyl- or aralkylsulfonyl (for example, methanesulfonyl); (3) amino acid esters (for example, L-valyl or L- isoleucyl);
  • the compounds of Formula (I), (II), or (III) may contain asymmetric or chiral centers, and, therefore, exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of Formula (I), (II), or (III) as well as mixtures thereof, including racemic mixtures, form part of the present invention.
  • the present invention embraces all geometric and positional isomers. For example, if a compound of Formula (I), (II), or (III) incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the invention.
  • Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as, for example, by chromatography and/or fractional crystallization.
  • Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers.
  • an appropriate optically active compound e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride
  • some of the compounds of Formula (I), (II), or (III) may be atropisomers (e.g., substituted biaryls) and are considered as part of this invention. Enantiomers can also be separated by use of chiral HPLC column.
  • All stereoisomers for example, geometric isomers, optical isomers and the like
  • of the present compounds including those of the salts, solvates, esters and prodrugs of the compounds as well as the salts, solvates and esters of the prodrugs
  • those which may exist due to asymmetric carbons on various substituents including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this invention, as are positional isomers (such as, for example, 4-pyridyl and 3-pyridyl).
  • salt is intended to equally apply to the salt, solvate, ester and prodrug of enantiomers, stereoisomers, rotamers, tautomers, positional isomers, racemates or prodrugs of the inventive compounds.
  • the present invention also embraces isotopically-labelled compounds of the present invention which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as 2 H, 3 H, 13 C, 14 C, 15 N, 18 O 1 17 0, 31 P, 32 P, 35 S, 18 F, and 36 CI, respectively.
  • Certain isotopically-labelled compounds of Formula (I), (II), or (III) are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e., 3 H) and carbon-14 (i.e., 14 C) isotopes are particularly preferred for their ease of preparation and detectability.
  • lsotopically labelled compounds of Formula (I), (II), or (III) can generally be prepared by following procedures analogous to those disclosed in the Schemes and/or in the Examples hereinbelow, by substituting an appropriate isotopically labelled reagent for a non-isotopically labelled reagent.
  • Polymorphic forms of the compounds of Formula (I), (II), or (III), and of the salts, solvates, esters and prodrugs of the compounds of Formula (I), (II), or (III), are intended to be included in the present invention.
  • each variable appearing more than once may be independently selected from the definition for that variable.
  • the compounds of the present invention can have pharmacological properties, for example the compounds of Formula I, Il or III can be inhibitors of TACE (TNF- ⁇ ) and/or MMP activity.
  • the compounds of Formula I, Il or III can have anti-inflammatory activity and/or immunomodulatory activity and can be useful in the treatment of diseases including but not limited to septic shock, haemodynamic shock, sepsis syndrome, post ischaemic reperfusion injury, malaria, mycobacterial infection, meningitis, psoriasis, congestive heart failure, fibrotic diseases, cachexia, graft rejection, cancers such as cutaneous T-cell lymphoma, diseases involving angiogenesis, autoimmune diseases, skin inflammatory diseases, inflammatory bowel diseases such as Crohn's disease and colitis, osteo and rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, adult Still's disease, ureitis, Wegener's granulomatosis, Behcehe disease, S
  • a compound of the present invention may be co-administered or used in combination with disease-modifying antirheumatic drugs (DMARDS) such as methotrexate, azathioprine, leflunomide, pencillinamine, gold salts, mycophenolate mofetil, cyclophosphamide and other similar drugs.
  • DARDS disease-modifying antirheumatic drugs
  • NSAIDS such as piroxicam, naproxen, indomethacin, ibuprofen and the like
  • COX-2 selective inhibitors such as Vioxx® and Celebrex®
  • immunosuppressives such as steroids, cyclosporin, Tacrolimus, rapamycin and the like
  • biological response modifiers BRMs
  • other anti-inflammatory agents such as p38 kinase inhibitors, PDE4 inhibitors, other chemically different TACE inhibitors, chemokine receptor antagonists, Thalidomide and other small molecule inhibitors of pro-inflammatory cytokine production.
  • a compound of the present invention may be co-administered or used in combination with an H1 antagonist for the treatment of seasonal allergic rhinitis and/or asthma.
  • H1 antagonists may be, for example, Claritin®, Clarinex®, Allegra®, or Zyrtec®.
  • the invention provides a method for treating rheumatoid arthritis comprising administering a compound of the formula I, Il or III in combination with compound selected from the class consisting of a COX-2 inhibitor e.g. Celebrex® or Vioxx®; a COX-1 inhibitor e.g. Feldene®; an immunosuppressive e.g. methotrexate or cyclosporin; a steroid e.g. ⁇ -methasone; and anti-TNF- ⁇ compound, e.g. Enbrel® or Remicade®; a PDE IV inhibitor, or other classes of compounds indicated for the treatment of rheumatoid arthritis.
  • a COX-2 inhibitor e.g. Celebrex® or Vioxx®
  • COX-1 inhibitor e.g. Feldene®
  • an immunosuppressive e.g. methotrexate or cyclosporin
  • a steroid e.g. ⁇ -methasone
  • the invention provides a method for treating multiple sclerosis comprising administering a compound of the formula I, Il or III in combination with a compound selected from the group consisting of Avonex®, Betaseron, Copaxone or other compounds indicated for the treatment of multiple sclerosis.
  • TACE activity is determined by a kinetic assay measuring the rate of increase in fluorescent intensity generated by TACE catalyzed cleavage of an internally quenched peptide substrate (SPDL-3).
  • SPDL-3 internally quenched peptide substrate
  • the purified catalytic domain of recombinant human TACE (rhTACEc, Residue 215 to 477 with two mutation (S266A and N452Q) and a 6xHis tail) is used in the assay. It is purified from the baculovirus/Hi5 cells expression system using affinity chromatography.
  • the substrate SPDL-3 is an internally quenched peptide (MCA-Pro-Leu-Ala-Gln-Ala- Val-Arg-Ser-Ser-Ser-Dpa-Arg-NH2), with its sequence derived from the pro-TNF ⁇ cleavage site.
  • MCA is (7-Methoxycoumarin-4-yl)acetyl.
  • Dpa is N-3-(2,4- Dinitrophenyl)-L-2,3-diaminopropionyl.
  • a 50 ⁇ l assay mixture contains 20 mM HEPES, pH 7.3, 5 mM CaCI 2 , 100 ⁇ M ZnCI 2 , 2 % DMSO, 0.04% Methylcellulose, 30 ⁇ M SPDL-3, 70 pM rhTACEc and a test compound.
  • RhTACEc is pre-incubated with the testing compound for 90 min. at 25 0 C. Reaction is started by addition of the substrate. The fluorescent intensity (excitation at 320 nm, emission at 405 nm) was measured every 45 seconds for 30 min. using a fluorospectrometer (GEMINI XS, Molecular Devices). Rate of enzymatic reaction is shown as Units per second. Effect of a test compound is shown as % of TACE activity in the absence of the compound.
  • Useful compounds for TACE inhibitory activity can exhibit Ki values of less than about 1000 nm, preferably about 0.01 nm to about 1000 nm, more preferably about 0.1 nm to about 100 nm, more preferably about 0.1 to about 15 nm, and most preferably less that about 15 nm.
  • Ki values The TACE inhibitory activity (Ki values) of some representative compounds of the present invention are listed in the "EXAMPLES" section hereinbelow.
  • compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
  • Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients that are suitable for the manufacture of tablets.
  • excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc.
  • the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the technique described in the U.S. Pat. Nos. 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for controlled release.
  • Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredients is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or a soft gelatin capsules where in the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.
  • an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
  • an oil medium for example peanut oil, liquid paraffin or olive oil.
  • Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions.
  • excipients are suspending agents, for example, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethyl-cellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example, heptadecaethylene-oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example, polyethylene sorb
  • the aqueous suspensions may also contain one or more preservatives, for example, ethyl or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.
  • preservatives for example, ethyl or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.
  • Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example, arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin.
  • the oily suspensions may contain a thickening agent, for example, beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
  • a dispersing or wetting agent e.g., sodium EDTA
  • suspending agent e.g., sodium EDTA
  • preservatives e.g., sodium EDTA, sodium sulfate, sodium bicarbonate
  • the pharmaceutical compositions of the invention may also be in the form of an oil-in-water emulsions.
  • the oily phase may be a vegetable oil, e.g., olive oil or arachis oil, or a mineral oil, e.g., liquid paraffin or mixtures of these.
  • Suitable emulsifying agents may be naturally-occurring phosphatides, e.g., soy beans, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example, sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, e.g., polyoxyethylene sorbitan monooleate.
  • the emulsions may also contain sweetening and flavoring agents.
  • Syrups and elixirs may be formulated with sweetening agents, for example, glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
  • sweetening agents for example, glycerol, propylene glycol, sorbitol or sucrose.
  • Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
  • the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension.
  • This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, e.g., as a solution in 1 ,3-butane diol.
  • the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid find use in the preparation of injectables.
  • compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • Such materials are cocoa butter and polyethylene glycols.
  • topical application For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing the compound of the invention are employed. (For purposes of this application, topical application shall include mouthwashes and gargles.)
  • the compounds for the present invention can be administered in the intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in the art.
  • the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.
  • Compounds of the present invention may also be delivered as a suppository employing bases such as cocoa butter, glycerinated gelatin, hydrogenated vegetable oils, mixtures of polyethylene glycols of various molecular weights and fatty acid esters of polyethylene glycol.
  • the dosage regimen utilizing the compounds of the present invention is selected in accordance with a variety of factors including type, species, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound thereof employed.
  • a physician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the drug required to prevent, counter, arrest or reverse the progress of the condition.
  • Optimal precision in achieving concentration of drug within the range that yields efficacy without toxicity requires a regimen based on the kinetics of the drug's availability to target sites. This involves a consideration of the distribution, equilibrium, and elimination of a drug.
  • doses of the compound of Formula I, Il or III useful in the method of the present invention range from 0.01 to 1000 mg per day. Most preferably, dosages range from 0.1 to 500 mg/day.
  • the compositions are preferably provided in the form of tablets containing 0.01 to 1000 milligrams of the active ingredient, particularly 0.01 , 0.05, 0.1 , 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100 and 500 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated.
  • An effective amount of the drug is ordinarily supplied at a dosage level of from about 0.0002 mg/kg to about 50 mg/kg of body weight per day. The range is more particularly from about 0.001 mg/kg to 1 mg/kg of body weight per day.
  • the active agent of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in dividend doses of two, three or four time daily.
  • the amount of active ingredient that may be combined with the carrier materials to produce single dosage form will vary depending upon the host treated and the particular mode of administration.
  • the compounds of the invention may be produced by processes known to those skilled in the art and as shown in the following reaction schemes and in the preparations and examples described below.
  • dichloromethane DCM
  • TBAB tetrabutylammonium bromide
  • MeCN Benzyl
  • EtOAc acetonitrile
  • Tetrahydrofuran THF
  • Trifluoroacetic acid THF
  • HAAt 1-hydroxy-7-aza-benzotriazole
  • HAAt 1- hydroxylbenzotriazole(HOAt)
  • NMM N-methylmorpholine
  • EDCI diisopropylethyl amine
  • DMEA 1-hydroxybenzotriazole
  • the compounds in the invention may be produced by processes known to those skilled in the art and as shown in the following reaction schemes and in the preparations and examples described below.
  • Table 1 contains the compounds with retention time/observed MW and/or NMR data.
  • the compounds of Table 1 can be obtained using synthetic methods similar to those below as listed in the last column of Table 1 using appropriate reagents known to those skilled in the art. Method A
  • Compound F2 is generated using procedures similar to Method A Step 1. Method F; Step 2.
  • Compound F3 is generated using procedures similar to method A step 2 and 3. Method F; Step 3.
  • Compound F4 is generated using a literature procedure (JACS, 123, 2001 , 10770). To a toluene solution of 2-phenylquinolin-4-yl-methanol (0.3 mmol) is added F3 (0.150 mmol), Cs 2 CO 3 (0.375 mmol), palladium acetate (12 mg) and 1 ,1 '-binaphthyl-2-yl-di-t-butyl phosphine (30 mg). The reaction mixture is flushed with Nitrogen followed by heating at 110 0 C overnight. The reaction mixture is then cooled to r.t. before it is chromatographed via a silica gel column to give F4.
  • Compound F5 is obtained using procedures similar to Method A, Step 4, 5 and 7.
  • those compounds having a Ki value of less than 20 nM are designated with letter "A”; those with a Ki value of from 20 to less than 100 nM (10 - ⁇ 100 nM) are designated with letter "B”; those with a Ki value of from 100 to 1000 nM are designated with letter "C”; and those with a Ki value of more than 1000 nM (>1000 nM) are designated with letter "D”.

Abstract

This invention relates to compounds of the Formula (I): Chemical formula should be inserted here as it appears on the abstract in paper form. or a pharmaceutically acceptable salt, solvate or isomer thereof, wherein n, M, V, T, W, X, U, R1 and R2 are as disclosed in the present specification, and which compounds are useful for the treatment of diseases or conditions mediated by MMPs, TNF- or combinations thereof.

Description

COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
BACKGROUND OF THE INVENTION Field of the Invention
This invention relates to hydroxamic or carboxylic acid functional compounds that can inhibit the production of tumor necrosis factor alpha (TNF-α), pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.
Description
Tumor necrosis factor alpha (TNF-α) has been shown to play a pivotal role in immune and inflammatory responses. Inappropriate or over-expression of TNF- α is a hallmark of a number of diseases, including rheumatoid arthritis (RA), Crohn's disease and sepsis. Inhibition of TNF-α production has been shown to be beneficial in many preclinical models of inflammatory disease, making inhibition of TNF-α production or signaling an appealing target for the development of novel anti-inflammatory drugs.
Tumor necrosis factor alpha is a cell-associated cytokine that is processed from a 26 kd precursor form to a 17 kd active form. See Black R.A. "Tumor necrosis factor-alpha converting enzyme" lnt J Biochem Cell Biol. 2002 Jan;34(1):1-5 and Moss ML, White JM, Lambert MH, Andrews RC1TACE and other ADAM proteases as targets for drug discovery" Drug Discov Today. 2001 Apr 1 ;6(8):417-426, each of which is incorporated by reference herein.
TNF-α has been shown to be a primary mediator in humans and animals of inflammation, fever and acute phase responses, similar to those observed during acute infection and shock. Excess TNF-α has been shown to be lethal. Blocking the effects of TNF-α with specific antibodies can be beneficial in a variety of conditions, including autoimmune diseases such as rheumatoid arthritis (Feldman et al, Lancet, (1994) 344, 1105), non-insulin dependent diabetes mellitus (Lohmander L. S. et al., Arthritis Rheum. 36 (1993) 1214-22) and Crohn's disease (Macdonald T. et al., Clin. Exp. Immunol. 81 (1990) 301 ). Metalloproteinases (MP) are important in the uncontrolled breakdown of connective tissue, including proteoglycan and collagen, leading to resorption of the extracellular matrix. This is a feature of many pathological conditions, such as rheumatoid and osteo- arthritis, corneal, epidermal or gastric ulceration; tumor metastasis or invasion; periodontal disease and bone disease. Normally these catabolic enzymes are tightly regulated at the level of their synthesis as well as at their level of extracellular activity through the action of specific inhibitors, such as alpha-2-macroglobulins and TIMP (tissue inhibitor of metalloproteinase), which form inactive complexes with the MP's.
Osteo- and rheumatoid arthritis (OA and RA, respectively) are destructive diseases of articular cartilage characterized by localized erosion of the cartilage surface. Findings have shown that articular cartilage from the femoral heads of patients with OA, for example, had a reduced incorporation of radiolabeled sulfate over controls, suggesting that there must be an enhanced rate of cartilage degradation in OA (Mankin et al. J. Bone Joint Surg. 52A (1970) 424-434). There are four classes of protein degradative enzymes in mammalian cells: serine, cysteine, aspartic and metalloproteinases. The available evidence supports that it is the metalloproteinases that are responsible for the degradation of the extracellular matrix of articullar cartilage in OA and RA. Increased activities of collagenases and stromelysin have been found in OA cartilage and the activity correlates with severity of the lesion (Mankin et al. Arthritis Rheum. 21 , 1978, 761- 766, Woessner et al. Arthritis Rheum. 26, 1983, 63-68 and Ibid. 27, 1984, 305- 312). In addition, aggrecanase (a newly identified metalloproteinase enzymatic activity) has been identified that provides the specific cleavage product of proteoglycan, found in RA and OA patients (Lohmander L. S. et al. Arthritis Rheum. 36, 1993, 1214-22).
Therefore, metalloproteinases (MP) have been implicated as the key enzymes in the destruction of mammalian cartilage and bone. It can be expected that the pathogenesis of such diseases can be modified in a beneficial manner by the administration of MP inhibitors, and many compounds have been suggested for this purpose (see Wahl et al. Ann. Rep. Med. Chem. 25, 175-184, AP, San Diego, 1990). Compounds that inhibit the production of TNF-α are therefore of therapeutic importance for the treatment of inflammatory disorders. Recently it has been shown that a matrix metalloproteinase (MMP) or family of metalloproteinases, hereafter known as TNF-α convertases (TACE), as well as other MP's are capable of converting TNF-α from its inactive to active form (Gearing et al Nature, 1994, 370, 555). Since excessive TNF-α production has been noted in several disease conditions also characterized by MMP-mediated tissue degradation, compounds which inhibit both MMPs and TNF-α production may also have a particular advantage in diseases where both mechanisms are involved.
U.S. Patent 6,838,466 refers to hydroxamic or carboxylic acid functional compounds that can inhibit the production of tumor necrosis factor alpha (TNF-α).
WO03/053940 refers to barbituric acid derivatives useful as TNF-α converting enzyme (TACE) and matrix metalloproteinase (MMP) inhibitors.
W095/09841 describes compounds that are hydroxamic acid derivatives and are inhibitors of cytokine production.
European Patent Application Publication No. 574,758 A1 , discloses hydroxamic acid derivatives as collagenase inhibitors. GB 2 268 934 A and WO 94/24140 claim hydroxamate inhibitors of MMPs as inhibitors of TNF-α production.
There is a need in the art for inhibitors of MMPs, in particular TNF-α convertase, which can be useful as anti-inflammatory compounds and cartilage protecting therapeutics. The inhibition of TNF-α convertase and other metalloproteinases can prevent the degradation of cartilage by these enzymes, thereby alleviating the pathological conditions of osteo- and rheumatoid arthritis.
SUMMARY OF THE INVENTION
In its many embodiments, the present invention provides a novel class of compounds as inhibitors of TACE, the production of TNF-α, MMPs, ADAMs or any combination thereof, methods of preparing such compounds, pharmaceutical compositions comprising one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition or amelioration of one or more diseases associated with TACE, TNF-σ, MMPs, ADAMs or any combination thereof using such compounds or pharmaceutical compositions.
In one embodiment, the present application discloses a compound having the general structure shown in Formula (I):
Figure imgf000005_0001
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein:
M, together with the two carbon atoms to which it is shown attached in formula (I) is 4-7 membered hetereocyclyl or heterocyclenyl comprising 0-3 carbonyl groups,
0-3 double bonds, and 1-3 heteroatoms selected from O, N, and S, wherein said
4-7 membered hetereocyclyl or heterocycienyl can, in addition to the four substituents V, R2, T, and -(W)n-X-U-R1 as set forth in formula (I), be further optionally substituted with R21;
T is selected from the group consisting of H, alkyl, R21 -substituted alkyl, cycloalkyl, aryl, heteroaryl, hetereocyclyl, arylalkyl, heteroarylalkyl, -OR3, -C(O)R4, -C(O)OR3,
-C(O)NR24R25, -C(O)NR24OR3, -C(O)SR3, -NR24R25, -NR25C(O)R4, -NR25C(O)OR3,
-NR25C(O)NR24R25, -NR25C(O)NR24OR3, -SR3, -N(R24)S(O)2R25, -S(O)xNR24R25, -
S(O)xNR25OR3, -CN, -P(O)(R24XOR24), -P(O)(OR24)(OR24), -C(R4)(=N(OR3)), -
C(O)-N(R31 )CH(R32)-C(O)NR24R25 and
-C(O)N(R31)CH(R32)-C(O)-NR25OR3, wherein each of the cycloalkyl, aryl, heteroaryl, hetereocyclyl, arylalkyl and heteroarylalkyl groups of T is unsubstituted or optionally independently substituted with one to six R20 moieties which can be the same or different, each R20 moiety being independently selected from the group of R20 moieties below;
V is selected from the group consisting of alkyl, R21 -substituted alkyl, cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl, heteroaryl, -OR3, -C(O)R4, -(CR23R24)ni C(O)OR3, -C(O)NR24R25, -(CR23R24)n1C(O)NR25OR3, -C(O)SR3, -C(R23)(R24)SH, -NR24R25, -NR25C(O)R4, -NR25C(O)OR3, -NR25C(O)NR24R25, -NR25C(O)NR24OR3, -SR3, -S(O)xNR24R25, -S(O)xNR25OR3, -CN, -P(O)(R25XOR24), -P(O)(OR24)(OR24), -C(R4X=N(OR3)), -C(O)-N(R31)CH(R32)-C(O)NR24R25 and -C(O)N(R31)CH(R32)-C(O)-NR25OR3, wherein each of the cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl and heteroaryl groups of V is unsubstituted or optionally independently substituted with one to three R20 moieties which can be the same or different, each R20 moiety being independently selected from the group of R20moieties below;
W is selected from the group consisting of
Figure imgf000006_0001
a covalent bond, -(C(R3)(R4))n2-, -0-, -S-, -N(R24)-, and -N(Z)-;
X is selected from the group consisting of alkyl, cylcloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl, heteroaryl and -C^≡C- ; wherein each of the alkyl, cylcloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl groups of X is unsubstituted or optionally independently substituted with one to four selected R20 moieties which can be the same or different, each R20 moiety being independently selected from the group of R20 moieties below,
U is selected from the group consisting of a covalent bond,
-(C(R3)(R4))P-, -Y-(C(R3)(R4))q-, -(C(R3)(R4))t-Y-, -N(R3XZ)-Q-, -Q-N(R3)(Z)- and -Y-;
Q is selected from the group consisting of -S(O)-, -S(O)2-, -C(O)-, and - C(O)NR4-;
Y is selected from the group consisting of -O-, -S(O)x-, -N(Z)-, -N(R4)(Z); - C(O)-, -OC(O)-, -C(O)N(R24)-, -N(R24)C(O)N(R25)-, -N(R24)S(O)-, -N(R24)S(O)2-, -S(O)N(R24)-, and -S(O)2N(R24)-; Z is selected from the group consisting of -R3, -C(O)R3, -S(O)xR3 and -C(O)NR3R4; n is 0 to 2; n1 is O to 2; n2 is 1 to 2; p is 1 to 4; q is 1 to 4; t is 1 to 4; v is 1 to 3; x is 0 to 2; y is 0 to 3;
R1 is selected from the group consisting of alkyl, R21-substituted alkyl, cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl, heteroaryl, -C^CR and -CR3=CR4R5, wherein each of the alkyl, cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl and heteroaryl groups of R1 is unsubstituted or optionally independently substituted with one to six R20 moieties which can be the same or different, each R20 moiety being independently selected from the group of R20 moieties below, each of R2, R4 and R5 is the same or different and each is independently selected from the group consisting of H, halo, alkyl, R22-substituted alkyl, cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl, heteroaryl, -OR6, -C(O)R7, -C(O)OR6, -NR24R25, -NR24C(O)R25, -N(=C-O-NR24R25), and -NR24S(O)2R25, wherein each of the cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl and heteroaryl groups of R2, R4 and R5 is unsubstituted or optionally independently substituted with one to six alkyl, R22-substituted alkyl or R22 moieties which can be the same or different, each R22 moiety being independently selected from the group of R22 moieties below; each R3 is the same or different and is independently selected from the group consisting of H, alkyl, R22-substituted alkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl, heteroaryl, -OR6, -C(O)R7, -C(O)OR6, -NR24R25, -NR24C(O)R25, -N(=C-O-NR24R25) and -NR24S(O)2R25, wherein each of the cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl and heteroaryl groups of R3 is unsubstituted or optionally independently substituted with one to four alkyl, R22-substituted alkyl or R22 moieties which can be the same or different, each R22 moiety being independently selected from the group of R22 moieties below; each R6 is independently selected from the group consisting of H, alkyl and -OCF3; each R7 is independently selected from the group consisting of H, alkyl, heteroaryl and -CF3; each R20 is independently selected from the group consisting of: alkyl, R21- substituted alkyl, -OR3, halo, (=O), -CN, -NO2, -NR24R25, -C(O)R3, -C(O)OR3, - C(O)NR24R25, -S(O)xNR24R25, -S(O)xR5, -CF3, -OCF3, -CF2CF3, -CH(=NOH), - C(=NOH)R3, aryl, heteroaryl, cycloalkyl, hetereocyclyl, -N(R25)S(O)XR5, - N(R25)C(O)R5, and -N(R25)C(O)NR24R25, wherein each of the aryl, heteroaryl, cycloalkyl and hetereocyclyl groups of R20 is unsubstituted or optionally independently substituted with one to four R22 moieties which can be the same or different, each R22 moiety being independently selected from the group of R22 moieties below, or two R20 groups taken together with the carbon to which both R20 groups
are attached
Figure imgf000008_0001
R21 is one to three substituents independently selected from the group consisting of: -OR3, halo, -CN, -NO2, -NR24R25, -C(O)R3, -C(O)OR3, -C(O)NR24R25, -S(O)xNR24R25, -SOxR5, -CF3, -OCF3, -CF2CF3, -C(=NOH)R3, R23- substituted alkyl, aryl, heteroaryl, cycloalkyl, hetereocyclyl, -N(R25)S(O)XR5, - N(R25)C(O)R5, and -N(R25)C(O)NR24R25; wherein each of the aryl, heteroaryl, cycloalkyl, and hetereocyclyl groups of R21 is unsubstituted or optionally independently substituted with one to four R23 moieties which can be the same or different, each R23 moiety being independently selected from the group of R23 moieties below, or two R21 groups taken together with the carbon to which both R21 groups
are attached
Figure imgf000009_0001
each R22 is independently selected from the group consisting of: halo, alkynyl, aryl, heteroaryl, -OR24, -(Ci-C6 alkyl)-OR24, -CN, -NO2, -NR24R25, -C(O)R23, -C(O)OR23, -C(O)NR24R25, -S(O)xNR24R25, -S(O)xR23, - CF3, -OCF3, -CF2CF3, -C(=NOH)R23, -N(R24)S(O)XR25, -N(R24)C(O)R25, and - N(R24)C(O)NR24R25, or two R22 groups taken together with the carbon to which both R22 groups
are attached is
Figure imgf000009_0002
each R23 is independently selected from the group consisting of H, hydroxyl, halo and alkyl; each R24 is independently selected from the group consisting of H and alkyl; each R25 is independently selected from the group consisting of H, hydroxyl, alkyl, hydroxyalkyl, aryl, cycloalkyl, heteroaryl, -NR24R24 , -(C1 to C6 alkyl)NR24N24, -CF3 and -S(O)xR23;
R26 is selected from the group consisting of H, alkyl, cycloalkyl, aryl, and heteroaryl;
R27 is selected from the group consisting of H, alkyl, cycloalkyl, aryl, and heteroaryl; and each of R31 and R32 is the same or different and wherein each is independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, heteroaryl, -NR24R25, -(CHs)3NH(C=NH)NH2, -CH2C(O)NH2, -CH2C(O)OH, - CH2SH, -CH2S-SCH2CH(NH2)C(O)OH,
-CH2CH2C(O)OH, -CH2CH2C(O)NH2, -(CH2)4NH2) -CH2CH2CH(OH)CH2NH2, -CH2CH(CHs)2, -CH(CH3)CH2(CH3), -CH2CH2SCH3, -CH2OH, -CH(OH)(CH3),
Figure imgf000010_0001
or R31 and R32, together with the N to which R31 is attached and the C to which R31 is attached, form a 5-membered ring which is unsubstituted or optionally independently substituted with a hydroxyl group.
In another embodiment, the present invention discloses a compound represented by the structural formula (II):
Figure imgf000010_0002
or a pharmaceutically acceptable salt, solvate or ester of said compound, wherein:
L is aryl or heteroaryl;
R1 is selected from the group consisting of alkyl, R21 -substituted alkyl, cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl, heteroaryl, -C^CR and -CR3=CR4R5, wherein each of the alkyl, cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl and heteroaryl groups of R1 is unsubstituted or optionally independently substituted with one to six R20 moieties which can be the same or different, each R20 moiety being independently selected from the group of R20 moieties below, T is selected from the group consisting of H, alkyl, R21 -substituted alkyl, cycloalkyl, aryl, heteroaryl, hetereocyclyl, arylalkyl, heteroarylalkyl, -OR3, -C(O)R4, -C(O)OR3, -C(O)NR24R25, -C(O)NR24OR3, -C(O)SR3, -NR24R25, -NR25C(O)R4, -NR25C(O)OR3, -NR25C(O)NR24R25, -NR25C(O)NR24OR3, -SR3, -N(R24)S(O)2R25, -S(O)xNR24R25, - S(O)xNR25OR3, -CN, -P(O)(R24XOR24), -P(O)(OR24)(OR24), -C(R4X=N(OR3)), - C(O)-N(R31 )CH(R32)-C(O)NR24R25 and -C(O)N(R31)CH(R32)-C(O)-NR25OR3, wherein each of the cycloalkyl, aryl, heteroaryl, hetereocyclyl, arylalkyl and heteroarylalkyl groups of T is unsubstituted or optionally independently substituted with one to six R20 moieties which can be the same or different, each R20 moiety being independently selected from the group of R20 moieties below;
G1 is O, H, alkyl, R21-substituted alkyl, -OR3, halo, -C(O)R3, -C(O)OR3, - C(O)NR24R25, -S(O)xNR24R25, -S(O)xR5, -CF3, -OCF3, -CF2CF3, -C(=NOH)R3, aryl, heteroaryl, cycloalkyl, hetereocyclyl, and heteroarylalkyl, wherein each of the aryl, heteroaryl, cycloalkyl, hetereocyclyl and heteroarylalkyl groups of P is unsubstituted or optionally independently substituted with one to four R23 moieties which can be the same or different, each R23 moiety being independently selected from the group of R23 moieties below,
V is selected from the group consisting of alkyl, R21 -substituted alkyl, cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl, heteroaryl, -OR3, -C(O)R4, -(CR23R24)ni C(O)OR3, -C(O)NR24R25,
-(CR23R24)niC(O)NR25OR3, -C(O)SR3, -C(R23)(R24)SH, -NR24R25, NR25C(O)R4, -NR25C(O)OR3, -NR25C(O)NR24R25, -NR25C(O)NR24OR3, -SR3, -S(O)xNR24R25, -S(O)xNR25OR3, -CN, -P(O)(R25)(OR24), -P(O)(OR24)(OR24), -C(R4X=N(OR3)), -C(O)-N(R31)CH(R32)-C(O)NR24R25 and -C(O)N(R31)CH(R32)-C(O)-NR25OR3, wherein each of the cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl and heteroaryl groups of V is unsubstituted or optionally independently substituted with one to three R20 moieties which can be the same or different, each R20 moiety being independently selected from the group of R20moieties below; n1 is O to 2; x is O to 2; each of R2, R4 and R5 is the same or different and each is independently selected from the group consisting of H, halo, alkyl, R22-substituted alkyl, cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl, heteroaryl, -OR6, -C(O)R7, -C(O)OR6, -NR24R25, -NR24C(O)R25, -N(=C-O-NR24R25), -NR24S(O)2R25, wherein each of the cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl and heteroaryl groups of R2, R4 and R5 is unsubstituted or optionally independently substituted with one to six alkyl, R22-substituted alkyl or R22 moieties which can be the same or different, each R22 moiety being independently selected from the group of R22 moieties below, or R4 and R5 taken together with the carbon to which both R4 and R5 are
attached i iss
Figure imgf000012_0001
each R )3 is the same or different and is independently selected from the group consisting of H, alkyl, R22-substituted alkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl, heteroaryl, -OR6, -C(O)R7, -C(O)OR6, -NR24R25, -NR24C(O)R25, -N(=C-O-NR24R25) and -NR24S(O)2R25, wherein each of the cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl and heteroaryl groups of R3 is unsubstituted or optionally independently substituted with one to four alkyl, R22-substituted alkyl or R22 moieties which can be the same or different, each R22 moiety being independently selected from the group of R22 moieties below; each R6 is independently selected from the group consisting of H, alkyl and -OCF3; each R7 is independently selected from the group consisting of H, alkyl, heteroaryl and -CF3; each R20 is independently selected from the group consisting of: alkyl, R21- substituted alkyl, -OR3, halo, -CN, -NO2, -NR24R25, -C(O)R3, -C(O)OR3, -C(O)NR24R25, -S(O)xNR24R25, -S(O)xR5, -CF3, -OCF3, -CF2CF3, -C(=NOH)R3, aryl, heteroaryl, cycloalkyl, hetereocyclyl, -N(R25)S(O)XR5, - N(R25)C(O)R5, and -N(R25)C(O)NR24R25, wherein each of the aryl, heteroaryl, cycloalkyl and hetereocyclyl groups of R20 is unsubstituted or optionally independently substituted with one to four R22 moieties which can be the same or different, each R22 moiety being independently selected from the group of R23 moieties below, or two R20 groups taken together with the carbon to which both R20 groups
are attached
Figure imgf000013_0001
R21 is one to three substituents independently selected from the group consisting of: -OR3, halo, -CN, -NO2, -NR24R25, -C(O)R3, -C(O)OR3, -C(O)NR24R25, -S(O)xNR24R25, -SOxR5, -CF3, -OCF3, -CF2CF3, -C(=NOH)R3, R23- substituted alkyl, aryl, heteroaryl, cycloalkyl, hetereocyclyl, -N(R25)S(O)XR5, - N(R25)C(O)R5, and -N(R25)C(O)NR24R25; wherein each of the aryl, heteroaryl, cycloalkyl, and hetereocyclyl groups of R21 is unsubstituted or optionally independently substituted with one to four R23 moieties which can be the same or different, each R23 moiety being independently selected from the group of R23 moieties below, or two R21 groups taken together with the carbon to which both R21 groups
are attached
Figure imgf000013_0002
each R22 is independently selected from the group consisting of: halo, alkynyl, aryl, heteroaryl, -OR24, -(C1-C6 alkyl)-OR24, -CN, -NO2, -NR24R25, -C(O)R23, -C(O)OR23, -C(O)NR24R25, -S(O)xNR24R25, -S(O)xR23, - CF3, -OCF3, -CF2CF3, -C(=NOH)R23, -N(R24)S(O)XR25, -N(R24)C(O)R25, and - N(R24)C(O)NR24R25, or two R22 groups taken together with the carbon to which both R22 groups
are attached is
Figure imgf000013_0003
each R23 is independently selected from the group consisting of H, hydroxyl, halo and alkyl; each R24 is independently selected from the group consisting of H and alkyl; each R25is independently selected from the group consisting of H, hydroxyl, alkyl, hydroxyalkyl, aryl, cycloalkyl, heteroaryl, -NR24R24 , -(Ci to C6 alkyl)NR24N24, -CF3 and -S(O)xR23; each of R31 and R32 is the same or different and wherein each is independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, heteroaryl, -NR24R25,
Figure imgf000014_0001
-CH2C(O)NH2, -CH2C(O)OH, -CH2SH, -CH2S-SCH2CH(NH2)C(O)OH, -CH2CH2C(O)OH, -CH2CH2C(O)NH2, -(CH2)4NH2, -CH2CH2CH(OH)CH2NH2, -CH2CH(CHs)2, -CH(CH3)CH2(CH3), -CH2CH2SCH3, -CH2OH, -CH(OH)(CH3),
Figure imgf000014_0002
or R31 and R32, together with the N to which R31 is attached and the C to which R31 is attached, form a 5-membered ring which is unsubstituted or optionally independently substituted with a hydroxyl group.
In another embodiment, the present invention provides a compound of formula (III)
Figure imgf000015_0001
Formula HI or a pharmaceutically acceptable salt, solvate or ester of said compound, wherein:
L is aryl or heteroaryl;
R1 is selected from the group consisting of alkyl, R21 -substituted alkyl, cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl, heteroaryl, -C^≡CR and -CR3=CR4R5, wherein each of the alkyl, cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl and heteroaryl groups of R1 is unsubstituted or optionally independently substituted with one to six R20 moieties which can be the same or different, each R20 moiety being independently selected from the group of R20 moieties below,
T is selected from the group consisting of H, alkyl, R21 -substituted alkyl, cycloalkyl, aryl, heteroaryl, hetereocyclyl, arylalkyl, heteroarylalkyl, -OR3, -C(O)R4, -C(O)OR3, -C(O)NR24R25, -C(O)NR24OR3, -C(O)SR3, -NR24R25, -NR25C(O)R4, - NR25C(O)OR3, -NR25C(O)NR24R25, -NR25C(O)NR24OR3, -SR3, -N(R24JS(O)2R25, - S(O)xNR24R25, -S(O)xNR25OR3, -CN, -P(O)(R24)(OR24), -P(O)(OR24)(OR24), - C(R4X=N(OR3)), -C(O)-N(R31)CH(R32)-C(O)NR24R25 and -C(O)N(R31)CH(R32)-C(O)-NR25OR3, wherein each of the cycloalkyl, aryl, heteroaryl, hetereocyclyl, arylalkyl and heteroarylalkyl groups of T is unsubstituted or optionally independently substituted with one to six R20 moieties which can be the same or different, each R20 moiety being independently selected from the group of R20 moieties below;
G2 is H, alkyl, R21-substituted alkyl, -OR3, halo, -C(O)R3, -C(O)OR3, - C(O)NR24R25, -S(O)xNR24R25, -S(O)xR5, -CF3, -OCF3, -CF2CF3, -C(=NOH)R3, aryl, heteroaryl, cycloalkyl, hetereocyclyl, and heteroarylalkyl, wherein each of the aryl, heteroaryl, cycloalkyl, hetereocyclyl and heteroarylalkyl groups of Q is unsubstituted or optionally independently substituted with one to four R23 moieties which can be the same or different, each R23 moiety being independently selected from the group of R23 moieties below,
V is selected from the group consisting of alkyl, R21 -substituted alkyl, cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl, heteroaryl, -OR3, -C(O)R4, -(CR23R24)niC(O)OR3, -C(O)NR24R25,
-(CR23R24)ni C(O)NR25OR3, -C(O)SR3, -C(R23)(R24)SH, -NR24R25, NR25C(O)R4, -NR25C(O)OR3, -NR25C(O)NR24R25, -NR25C(O)NR24OR3, -SR3, -S(O)xNR24R25, -S(O)xNR25OR3, -CN, -P(O)(R25)(OR24), -P(O)(OR24)(OR24), -C(R4X=N(OR3)), -C(O)-N(R31)CH(R32)-C(O)NR24R25 and -C(O)N(R31)CH(R32)-C(O)-NR25OR3, wherein each of the cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl and heteroaryl groups of V is unsubstituted or optionally independently substituted with one to three R20 moieties which can be the same or different, each R20 moiety being independently selected from the group of R20moieties below; n1 is O to 2; x is O to 2; each of R2, R4 and R5 is the same or different and each is independently selected from the group consisting of H, halo, alkyl, R22-substituted alkyl, cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl, heteroaryl, -OR6, -C(O)R7, -C(O)OR6, -NR24R25, -NR24C(O)R25, -N(=C-O-NR24R25), -NR24S(O)2R25, wherein each of the cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl and heteroaryl groups of R2, R4 and R5 is unsubstituted or optionally independently substituted with one to six alkyl, R22-substituted alkyl or R22 moieties which can be the same or different, each R22 moiety being independently selected from the group of R22 moieties below, or R4 and R5 taken together with the carbon to which both R4 and R5 are
attached is
Figure imgf000016_0001
each R3 is the same or different and is independently selected from the group consisting of H, alkyl, R22-substituted alkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl, heteroaryl, -OR6, -C(O)R7, -C(O)OR6, -NR24R25, -NR24C(O)R25, -N(=C-O-NR24R25) and -NR24S(O)2R25, wherein each of the cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl and heteroaryl groups of R3 is unsubstituted or optionally independently substituted with one to four alkyl, R22-substituted alkyl or R22 moieties which can be the same or different, each R22 moiety being independently selected from the group of R22 moieties below; each R6 is independently selected from the group consisting of H, alkyl and -OCF3; each R7 is independently selected from the group consisting of H, alkyl, heteroaryl and -CF3; each R20 is independently selected from the group consisting of: alkyl, R21- substituted alkyl, -OR3, halo, -CN, -NO2, -NR24R25, -C(O)R3, -C(O)OR3, -C(O)NR24R25, -S(O)xNR24R25, -S(O)xR5, -CF3, -OCF3, -CF2CF3, -C(=NOH)R3, aryl, heteroaryl, cycloalkyl, hetereocyclyl, -N(R25)S(O)XR5, - N(R25)C(O)R5, and -N(R25)C(O)NR24R25, wherein each of the aryl, heteroaryl, cycloalkyl and hetereocyclyl groups of R20 is unsubstituted or optionally independently substituted with one to four R22 moieties which can be the same or different, each R22 moiety being independently selected from the group of R23 moieties below, or two R20 groups taken together with the carbon to which both R20 groups
are attached is
Figure imgf000017_0001
R21 is one to three substituents independently selected from the group consisting of: -OR3, halo, -CN, -NO2, -NR24R25, -C(O)R3, -C(O)OR3, -C(O)NR24R25, -S(O)xNR24R25, -SOxR5, -CF3, -OCF3, -CF2CF3, -C(=NOH)R3, R23- substituted alkyl, aryl, heteroaryl, cycloalkyl, hetereocyclyl, -N(R25)S(O)XR5, - N(R25)C(O)R5, and -N(R25)C(O)NR24R25; wherein each of the aryl, heteroaryl, cycloalkyl, and hetereocyclyl groups of R21 is unsubstituted or optionally independently substituted with one to four R23 moieties which can be the same or different, each R23 moiety being independently selected from the group of R23 moieties below, or two R21 groups taken together with the carbon to which both R21 groups
are attached
Figure imgf000018_0001
each R22 is independently selected from the group consisting of: halo, alkynyl, aryl, heteroaryl, -OR24, -(C1-C6 alkyl)-OR24, -CN, -NO2, -NR24R25, -C(O)R23, -C(O)OR23, -C(O)NR24R25, -S(O)xNR24R25, -S(O)xR23, - CF3, -OCF3, -CF2CF3, -C(=NOH)R23, -N(R24)S(O)XR25, -N(R24)C(O)R25, and - N(R24)C(O)NR24R25, or two R22 groups taken together with the carbon to which both R22 groups
Figure imgf000018_0002
each R23 is independently selected from the group consisting of H, hydroxyl, halo and alkyl; each R24 is independently selected from the group consisting of H and alkyl; each R25 Js independently selected from the group consisting of H, hydroxyl, alkyl, hydroxyalkyl, aryl, cycloalkyl, heteroaryl, -NR24R24 , -(Ci to C6 alkyl)NR24N24, -CF3 and -S(O)xR23; each of R31 and R32 is the same or different and wherein each is independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, heteroaryl, -NR24R25, -(CH2)SNH(C=NH)NH2,
-CH2C(O)NH2, -CH2C(O)OH1 -CH2SH, -CH2S-SCH2CH(NH2)C(O)OH, -CH2CH2C(O)OH, -CH2CH2C(O)NH2, -(CH2)4NH2, -CH2CH2CH(OH)CH2NH2, -CH2CH(CHa)2, -CH(CH3)CH2(CH3), -CH2CH2SCH3, -CH2OH, -CH(OH)(CH3),
Figure imgf000019_0001
Figure imgf000019_0002
Figure imgf000019_0003
or R31 and R32, together with the N to which R31 is attached and the C to which R31 is attached, form a 5-membered ring which is unsubstituted or optionally independently substituted with a hydroxyl group.
The compounds of Formula I, Il or III can be useful as inhibitors of and can be useful in the treatment and prevention of diseases associated with TACE, TNF- a, MMPs, ADAMs or any combination thereof.
DETAILED DESCRIPTION OF THE INVENTION
In its several embodiments, the present invention provides a novel class of inhibitors of MMP and TNF-α convertase, pharmaceutical compositions containing one or more of the compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention or amelioration of one or more of the symptoms of inflammation.
In one embodiment, the present invention provides compounds which are represented by structural Formula (I), (II) or (III) above or a pharmaceutically acceptable salt, solvate or ester of any of Formula (I), (II) or (III), wherein the various moieties are as described above.
In one embodiment, in the compound of formula (I), n is 1.
In one embodiment, in the compound of formula (I), M, together with the two carbon atoms to which it is shown attached in formula (I), represents a 4-5 membered hetereocyclyl or heterocyclenyl comprising 0-1 carbonyl groups, 0-1 double bonds, and 1 heteroatom selected from O, N, and S, wherein said 4-5 membered hetereocyclyl can, in addition to the four substituents V, R2, T, and - (W)n-X-U-R1 as set forth in formula (I), be further optionally substituted R21; T is selected from H and -C(O)OR3;
V is -C(O)R4 or -C(O)NR24R25, W is -(C(R3)(R4))n2-;
X is aryl, wherein said aryl is unsubstituted or optionally independently substituted with one to four selected R20 moieties which can be the same or different, each R20 moiety being independently selected from the group of R20 moieties below,
U is -Y-(C(R3)(R4))q-;
Y is -O-; n is 0 to 2; n2 is 1 to 2; q is 1 to 4; x is 0 to 2;
R1 is heteroaryl, wherein said heteroaryl group of R1 is unsubstituted or optionally independently substituted with one to six R20 moieties which can be the same or different, each R20 moiety being independently selected from the group of R20 moieties below, each R2, R4 and R5 is the same or different and each is independently selected from the group consisting of H, halo, alkyl, R22-substituted alkyl, cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl, heteroaryl, -OR6, -C(O)R7, -C(O)OR6, -NR24R25, -NR24C(O)R25, -N(=C-O-NR24R25), -NR24S(O)2R25, wherein each of the cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl and heteroaryl groups of R2, R4 and R5 is unsubstituted or optionally independently substituted with one to six alkyl, R22-substituted alkyl or R22 moieties which can be the same or different, each R22 moiety being independently selected from the group of R22 moieties below; each R3 is the same or different and is independently selected from the group consisting of H, alkyl, R22-substituted alkyl, cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl, heteroaryl, -OR6, -C(O)R7, -C(O)OR6, -NR24R25, -NR24C(O)R25, -N(=C-O-NR24R25) and -NR24S(O)2R25, each of the cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl and heteroaryl groups of R3 is unsubstituted or optionally independently substituted with one to four alkyl, R22-substituted alkyl or R22 moieties which can be the same or different, each R22 moiety being independently selected from the group of R22 moieties below; each R6 is independently selected from the group consisting of H, alkyl and -OCF3; each R7 is independently selected from the group consisting of H, alkyl, heteroaryl and -CF3; each R20 is independently selected from the group consisting of: alkyl, R21- substituted alkyl, -OR3, halo, -CN, -NO2, -NR24R25, -C(O)R3, -C(O)OR3, -C(O)NR24R25, -S(O)xNR24R25, -S(O)xR5, -CF3, -OCF3, -CF2CF3, -C(=NOH)R3, aryl, heteroaryl, cycloalkyl, hetereocyclyl, -N(R25)S(O)XR5, - N(R25)C(O)R5, and -N(R25)C(O)NR24R25, wherein each of the aryl, heteroaryl, cycloalkyl and hetereocyclyl groups of R20 is unsubstituted or optionally independently substituted with one to four R22 moieties which can be the same or different, each R22 moiety being independently selected from the group of R23 moieties below, or two R20 groups taken together with the carbon to which both R20 groups
are attached
Figure imgf000021_0001
R21 is one to three substituents independently selected from the group consisting of: -OR3, halo, -CN, -NO2, -NR24R25, -C(O)R3, -C(O)OR3, -C(O)NR24R25, -S(O)xNR24R25, -SOxR5, -CF3, -OCF3, -CF2CF3, -C(=NOH)R3, R23- substituted alkyl, aryl, heteroaryl, cycloalkyl, hetereocyclyl, -N(R25)S(O)XR5, - N(R25)C(O)R5, and -N(R25)C(O)NR24R25; wherein each of the aryl, heteroaryl, cycloalkyl, and hetereocyclyl groups of R21 is unsubstituted or optionally independently substituted with one to four R23 moieties which can be the same or different, each R23 moiety being independently selected from the group of R23 moieties below, or two R21 groups taken together with the carbon to which both R21 groups
are attached is
Figure imgf000022_0001
each R22 is independently selected from the group consisting of: halo, alkynyl, aryl, heteroaryl, -OR24, -(C1-C6 alkyl)-OR24, -CN, -NO2, -NR24R25, -C(O)R23, -C(O)OR23, -C(O)NR24R25, -S(O)xNR24R25, -S(O)xR23, - CF3, -OCF3, -CF2CF3, -C(=NOH)R23, -N(R24)S(O)XR25, -N(R24)C(O)R25, and - N(R24)C(O)NR24R25, or two R22 groups taken together with the carbon to which both R22 groups
are attached is
Figure imgf000022_0002
each R23 is independently selected from the group consisting of H, hydroxyl, halo and alkyl; each R24 is independently selected from the group consisting of H and alkyl; each R25 is independently selected from the group consisting of H, hydroxyl, alkyl, hydroxyalkyl, aryl, cycloalkyl, heteroaryl, -NR24R24 , -(C1 to C6 alkyl)NR24N24, -CF3 and -S(O)xR23.
In another embodiment, W is -CH2- in formula (I).
In another embodiment, U is -0-CH2- in formula (I).
In another embodiment, U is -OCH(CO2CH3)- in formula (I).
In another embodiment, T is H in formula (I).
In another embodiment, T is -C(O)OCH2CH3 in formula (I).
In another embodiment, V is -C(O)2H in formula (I).
In another embodiment, V is -C(O)NHOH in formula (I).
In another embodiment, in formula (I), M, togetherwith the two carbon atoms to which it is shown attached in formula (I), represents a 5 membered hetereocyclyl comprising 1 heteroatom selected from O, N, and S, wherein said 5 membered hetereocyclyl is only substituted with the four substituents V, R2, T, and -(W)n-X-U-R1 as set forth in formula (I).
In another embodiment, in formula (I), M, together with the two carbon atoms to which it is shown attached in formula (I), represents a 4 membered hetereocyclyl comprising 1 carbonyl group and 1 heteroatom selected from O, N, and S, wherein said 4 membered hetereocyclyl is only substituted with the four substituents V, R2, T, and -(W)n-X-U-R1 as set forth in formula (I).
In one embodiment, in formula (II), T is -C(O)OR3, wherein R3 is an alkyl.
In another embodiment, in formula (II), R1 is a heteroaryl with 1 heteroatom selected from S, O and N, wherein said heteroaryl is substituted with a phenyl moiety.
In another embodiment, in formula (II), R1 is a heteroaryl with 1 heteroatom selected from S, O and N, wherein said heteroaryl is substituted with a phenyl moiety, and wherein said heteroaryl is quinolinyl.
In another embodiment, in formula (II), R1 is
Figure imgf000023_0001
In another embodiment, in formula (II), V is -(CR23R24)n1 C(O)N R25OR3 wherein n1 is O, and both R3 and R25 are H.
In another embodiment, in formula (II), R2=R4=R5=H.
In another embodiment, in formula (II), L is aryl; in another embodiment said aryl is phenyl.
In one embodiment, in formula (III), G2 is H.
In another embodiment, in formula (III), T is H.
In another embodiment, in formula (III), wherein R2 and R5 are both hydrogen. In another embodiment, in formula (III), one of R3 and R4 is H, and the other is -C(O)OR6.
In another embodiment, in formula (III), both R3 and R4 are H.
In another embodiment, in formula (III), R1 is a heteroaryl with 1 heteroatom selected from S, O and N, wherein said heteroaryl is substituted with a phenyl moiety.
In another embodiment, in formula (III), R1 is a heteroaryl with 1 heteroatom selected from S, O and N, wherein said heteroaryl is substituted with a phenyl moiety, and wherein said heteroaryl is quinolinyl. In another embodiment, in formula (III), R1 is
Figure imgf000024_0001
In another embodiment, in formula (III), V is selected from the group consisting of -(CR23R24)niC(O)OR3 and -(CR23R24)n1C(O)NR25OR3 wherein n1 is 0 and both R3 and R25 are H.
In another embodiment, in formula (III), L is aryl; in another embodiment said aryl is phenyl.
In another embodiment, the compound of formula (I) is selected from the group consisting of:
Figure imgf000025_0001
or a pharmaceutically acceptable salt, solvate, or ester thereof.
As used above, and throughout this disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings:
"Patient" includes both human and animals.
"Mammal" means humans and other mammalian animals.
"Alkyl" means an aliphatic hydrocarbon group which may be straight or branched and comprising about 1 to about 20 carbon atoms in the chain. Preferred alkyl groups contain about 1 to about 12 carbon atoms in the chain. More preferred alkyl groups contain about 1 to about 6 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkyl chain. "Lower alkyl" means a group having about 1 to about 6 carbon atoms in the chain which may be straight or branched. "Alkyl" may be unsubstituted or optionally substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, aryl, cycloalkyl, cyano, hydroxy, alkoxy, alkylthio, amino, -NH(alkyl), -NH(cycloalkyl), -N(alkyl)2, carboxy and - C(O)O-alkyl. Non-limiting examples of suitable alkyl groups include methyl, ethyl, n-propyl, isopropyl and t-butyl.
The phrase "R21- substituted alkyl" means that the alkyl group can be substituted by one or more R21 substituents that may be the same or different, each substituent being independently selected from the group consisting of R21 substituents listed above. Each of the aryl, halo-substituted aryl, heteroaryl, cycloalkyl and heterocycloalkyl groups of R21 can be unsubstituted or independently substituted with one to four independently selected R23 moieties which can be the same or different, each R23 moiety being independently selected from the group of R23 moieties above.
The phrase "R22- substituted alkyl" means that the alkyl group can be substituted by one or more R22 substituents that may be the same or different, each substituent being independently selected from the group consisting of R22 substituents listed above.
The phrase "R52- substituted alkyl" means that the alkyl group can be substituted by one or more R52 substituents which may be the same or different, each substituent being independently selected from the group consisting of R21 substituents listed above.
"Alkenyl" means an aliphatic hydrocarbon group containing at least one carbon-carbon double bond and which may be straight or branched and comprising about 2 to about 15 carbon atoms in the chain. Preferred alkenyl groups have about 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 6 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkenyl chain. "Lower alkenyl" means about 2 to about 6 carbon atoms in the chain which may be straight or branched. "Alkenyl" may be unsubstituted or optionally substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of halo, alkyl. aryl, cycloalkyl, cyano, alkoxy and -S(alkyl). Non-limiting examples of suitable alkenyl groups include ethenyl, propenyl, n-butenyl, 3-methylbut-2-enyl, n- pentenyl, octenyl and decenyl.
"Alkylene" means a difunctional group obtained by removal of a hydrogen atom from an alkyl group that is defined above. Non-limiting examples of alkylene include methylene, ethylene and propylene.
"Alkynyl" means an aliphatic hydrocarbon group containing at least one carbon-carbon triple bond and which may be straight or branched and comprising about 2 to about 15 carbon atoms in the chain. Preferred alkynyl groups have about 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 4 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkynyl chain. "Lower alkynyl" means about 2 to about 6 carbon atoms in the chain which may be straight or branched. Non-limiting examples of suitable alkynyl groups include ethynyl, propynyl, 2-butynyl and 3-methylbutynyl. "Alkynyl" may be unsubstituted or optionally substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of alkyl, aryl and cycloalkyl.
"Aryl" means an aromatic monocyclic or multicyclic ring system comprising about 6 to about 14 carbon atoms, preferably about 6 to about 10 carbon atoms. The aryl group can be optionally substituted with one or more "ring system substituents" which may be the same or different, and are as defined herein. Non- limiting examples of suitable aryl groups include phenyl and naphthyl.
"Heteroaryl" means an aromatic monocyclic or multicyclic ring system comprising about 5 to about 14 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the ring atoms is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination. Preferred heteroaryls contain about 5 to about 6 ring atoms. The "heteroaryl" can be optionally substituted by one or more "ring system substituents" which may be the same or different, and are as defined herein. The prefix aza, oxa or thia before the heteroaryl root name means that at least a nitrogen, oxygen or sulfur atom respectively, is present as a ring atom. A nitrogen atom of a heteroaryl can be optionally oxidized to the corresponding N-oxide. Non-limiting examples of suitable heteroaryls include pyridyl, pyrazinyl, furanyl, thienyl, pyrimidinyl, pyridone (including N-substituted pyridones), isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, pyrazolyl, furazanyl, pyrrolyl, pyrazolyl, triazolyl, 1 ,2,4-thiadiazolyl, pyrazinyl, pyridazinyl, quinoxalinyl, phthalazinyl, oxindolyl, imidazo[1 ,2-a]pyridinyl, imidazo[2,1-b]thiazolyl, benzofurazanyl, indolyl, azaindolyl, benzimidazolyl, benzothienyl, quinolinyl, imidazolyl, thienopyridyl, quinazolinyl, thienopyrimidyl, pyrrolopyridyl, imidazopyridyl, isoquinolinyl, benzoazaindolyl, 1 ,2,4-triazinyl, benzothiazolyl and the like. The term "heteroaryl" also refers to partially saturated heteroaryl moieties such as, for example, tetrahydroisoquinolyl, tetrahydroquinolyl and the like.
"Aralkyl" or "arylalkyl" means an aryl-alkyl- group in which the aryl and alkyl are as previously described. Preferred aralkyls comprise a lower alkyl group. Non- limiting examples of suitable aralkyl groups include benzyl, 2-phenethyl and naphthalenylmethyl. The bond to the parent moiety is through the alkyl.
"Alkylaryl" means an alkyl-aryl- group in which the alkyl and aryl are as previously described. Preferred alkylaryls comprise a lower alkyl group. Non- limiting example of a suitable alkylaryl group is tolyl. The bond to the parent moiety is through the aryl.
"Cycloalkyl" means a non-aromatic mono- or multicyclic ring system comprising about 3 to about 10 carbon atoms, preferably about 5 to about 10 carbon atoms. Preferred cycloalkyl rings contain about 5 to about 7 ring atoms. The cycloalkyl can be optionally substituted with one or more "ring system substituents" which may be the same or different, and are as defined above. Non- limiting examples of suitable monocyclic cycloalkyls include cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl and the like. Non-limiting examples of suitable multicyclic cycloalkyls include 1-decalinyl, norbornyl, adamantyl and the like.
"Cycloalkylalkyl" means a cycloalkyl moiety as defined above linked via an alkyl moiety (defined above) to a parent core. Non-limiting examples of suitable cycloalkylalkyls include cyclohexyl methyl, adamantylmethyl and the like.
"Cycloalkenyl" means a non-aromatic mono or multicyclic ring system comprising about 3 to about 10 carbon atoms, preferably about 5 to about 10 carbon atoms which contains at least one carbon-carbon double bond. Preferred cycloalkenyl rings contain about 5 to about 7 ring atoms. The cycloalkenyl can be optionally substituted with one or more "ring system substituents" which may be the same or different, and are as defined above. Non-limiting examples of suitable monocyclic cycloalkenyls include cyclopentenyl, cyclohexenyl, cyclohepta-1 ,3- dienyl, and the like. Non-limiting example of a suitable multicyclic cycloalkenyl is norbomylenyl.
"Cycloalkenylalkyl" means a cycloalkenyl moiety as defined above linked via an alkyl moiety (defined above) to a parent core. Non-limiting examples of suitable cycloalkenylalkyls include cyclopentenylmethyl, cyclohexenylmethyl and the like.
"Halogen" means fluorine, chlorine, bromine, or iodine. Preferred are fluorine, chlorine and bromine.
"Ring system substituent" means a substituent attached to an aromatic or non-aromatic ring system which, for example, replaces an available hydrogen on the ring system. Ring system substituents may be the same or different, each being independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, alkylaryl, heteroaralkyl, heteroarylalkenyl, heteroarylalkynyl, alkylheteroaryl, hydroxy, hydroxyalkyl, alkoxy, aryloxy, aralkoxy, acyl, aroyl, halo, nitro, cyano, carboxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, alkylthio, arylthio, heteroarylthio, aralkylthio, heteroaralkylthio, cycloalkyl, heterocyclyl, -C(=N-CN)- NH2, -C(=NH)-NH2, -C(=NH)-NH(alkyl), YiY2N-, YiY2N-alkyl-, YiY2NC(O)-, YiY2NSO2- and -SO2NYiY2, wherein Yi and Y2 can be the same or different and are independently selected from the group consisting of hydrogen, alkyl, aryl, cycloalkyl, and aralkyl. "Ring system substituent" may also mean a single moiety which simultaneously replaces two available hydrogens on two adjacent carbon atoms (one H on each carbon) on a ring system. Examples of such moiety are methylene dioxy, ethylenedioxy, -C(CHs)2- and the like which form moieties such as, for example:
Figure imgf000029_0002
and
Figure imgf000029_0001
"Heteroarylalkyl" means a heteroaryl moiety as defined above linked via an alkyl moiety (defined above) to a parent core. Non-limiting examples of suitable heteroaryls include 2-pyridinylmethyl, quinolinylmethyl and the like.
"Heterocyclyl" means a non-aromatic saturated monocyclic or multicyclic ring system comprising about 3 to about 10 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the atoms in the ring system is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination. There are no adjacent oxygen and/or sulfur atoms present in the ring system. Preferred heterocyclyls contain about 5 to about 6 ring atoms. The prefix aza, oxa or thia before the heterocyclyl root name means that at least a nitrogen, oxygen or sulfur atom respectively is present as a ring atom. Any -NH in a heterocyclyl ring may exist protected such as, for example, as an -N(Boc), - N(CBz), -N(Tos) group and the like; such protections are also considered part of this invention. The heterocyclyl can be optionally substituted by one or more "ring system substituents" which may be the same or different, and are as defined herein. The nitrogen or sulfur atom of the heterocyclyl can be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide. Non-limiting examples of suitable monocyclic heterocyclyl rings include piperidyl, pyrrolidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, 1 ,4-dioxanyl, tetrahydrofuranyl, tetrahydrothiophenyl, lactam, lactone, and the like. "Heterocyclyl" may also include a single moiety (e.g., carbonyl) which simultaneously replaces two available hydrogens on the same carbon atom on a ring system. An example of such a heterocyclyl is pyrrolidone:
Figure imgf000030_0001
"Heterocyclylalkyl" means a heterocyclyl moiety as defined above linked via an alkyl moiety (defined above) to a parent core. Non-limiting examples of suitable heterocyclylalkyls include piperidinylmethyl, piperazinylmethyl and the like. "Heterocyclenyl" means a non-aromatic monocyclic or multicyclic ring system comprising about 3 to about 10 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the atoms in the ring system is an element other than carbon, for example nitrogen, oxygen or sulfur atom, alone or in combination, and which contains at least one carbon-carbon double bond or carbon-nitrogen double bond. There are no adjacent oxygen and/or sulfur atoms present in the ring system. Preferred heterocyclenyl rings contain about 5 to about 6 ring atoms. The prefix aza, oxa or thia before the heterocyclenyl root name means that at least a nitrogen, oxygen or sulfur atom respectively is present as a ring atom. The heterocyclenyl can be optionally substituted by one or more ring system substituents, wherein "ring system substituent" is as defined above. The nitrogen or sulfur atom of the heterocyclenyl can be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide. Non-limiting examples of suitable heterocyclenyl groups include 1 ,2,3,4- tetrahydropyridine, 1 ,2-dihydropyridyl, 1 ,4- dihydropyridyl, 1 ,2,3,6-tetrahydropyridine, 1 ,4,5,6-tetrahydropyrimidine, 2- pyrrolinyl, 3-pyrrolinyl, 2-imidazolinyl, 2-pyrazolinyl, dihydroimidazole, dihydrooxazole, dihydrooxadiazole, dihydrothiazole, 3,4-dihydro-2H-pyran, dihydrofuranyl, fluorodihydrofuranyl, 7-oxabicyclo[2.2.1]heptenyl, dihydrothiophenyl, dihydrothiopyranyl, and the like. "Heterocyclenyl" may also include a single moiety (e.g., carbonyl) which simultaneously replaces two available hydrogens on the same carbon atom on a ring system. An example of such a heterocyclenyl is pyrrolidinone:
Figure imgf000031_0001
"Heterocyclenylalkyl" means a heterocyclenyl moiety as defined above linked via an alkyl moiety (defined above) to a parent core.
It should be noted that in hetero-atom containing ring systems of this invention, there are no hydroxyl groups on carbon atoms adjacent to a N, O or S, as well as there are no N or S groups on carbon adjacent to another heteroatom. Thus, for example, in the ring:
Figure imgf000032_0001
there is no -OH attached directly to carbons marked 2 and 5.
It should also be noted that tautomeric forms such as, for example, the moieties:
Figure imgf000032_0002
are considered equivalent in certain embodiments of this invention.
"Alkynylalkyl" means an alkynyl-alkyl- group in which the alkynyl and alkyl are as previously described. Preferred alkynylalkyls contain a lower alkynyl and a lower alkyl group. The bond to the parent moiety is through the alkyl. Non-limiting examples of suitable alkynylalkyl groups include propargylmethyl.
"Heteroaralkyl" means a heteroaryl-alkyl- group in which the heteroaryl and alkyl are as previously described. Preferred heteroaralkyls contain a lower alkyl group. Non-limiting examples of suitable aralkyl groups include pyridylmethyl, and quinolin-3-ylmethyl. The bond to the parent moiety is through the alkyl.
"Hydroxyalkyl" means a HO-alkyl- group in which alkyl is as previously defined. Preferred hydroxyalkyls contain lower alkyl. Non-limiting examples of suitable hydroxyalkyl groups include hydroxymethyl and 2-hydroxyethyl.
"Acyl" means an H-C(O)-, alkyl-C(O)- or cycloalkyl-C(O)-, group in which the various groups are as previously described. The bond to the parent moiety is through the carbonyl. Preferred acyls contain a lower alkyl. Non-limiting examples of suitable acyl groups include formyl, acetyl and propanoyl.
"Aroyl" means an aryl-C(O)- group in which the aryl group is as previously described. The bond to the parent moiety is through the carbonyl. Non-limiting examples of suitable groups include benzoyl and 1- naphthoyl. "Alkoxy" means an alkyl-O- group in which the alky! group is as previously described. Non-limiting examples of suitable alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy and n-butoxy. The bond to the parent moiety is through the ether oxygen.
"Aryloxy" means an aryl-O- group in which the aryl group is as previously described. Non-limiting examples of suitable aryloxy groups include phenoxy and naphthoxy. The bond to the parent moiety is through the ether oxygen.
"Aralkyloxy" means an aralkyl-O- group in which the aralkyl group is as previously described. Non-limiting examples of suitable aralkyloxy groups include benzyloxy and 1 - or 2-naphthalenemethoxy. The bond to the parent moiety is through the ether oxygen.
"Alkylthio" means an alkyl-S- group in which the alkyl group is as previously described. Non-limiting examples of suitable alkylthio groups include methylthio and ethylthio. The bond to the parent moiety is through the sulfur.
"Arylthio" means an aryl-S- group in which the aryl group is as previously described. Non-limiting examples of suitable arylthio groups include phenylthio and naphthylthio. The bond to the parent moiety is through the sulfur.
"Aralkylthio" means an aralkyl-S- group in which the aralkyl group is as previously described. Non-limiting example of a suitable aralkylthio group is benzylthio. The bond to the parent moiety is through the sulfur.
"Alkoxycarbonyl" means an alkyl-O-CO- group. Non-limiting examples of suitable alkoxycarbonyl groups include methoxycarbonyl and ethoxycarbonyl. The bond to the parent moiety is through the carbonyl.
"Aryloxycarbonyl" means an aryl-O-C(O)- group. Non-limiting examples of suitable aryloxycarbonyl groups include phenoxycarbonyl and naphthoxycarbonyl. The bond to the parent moiety is through the carbonyl.
"Aralkoxycarbonyl" means an aralkyl-O-C(O)- group. Non-limiting example of a suitable aralkoxycarbonyl group is benzyloxycarbonyl. The bond to the parent moiety is through the carbonyl.
"Alkylsulfonyl" means an alkyl-S(O2)- group. Preferred groups are those in which the alkyl group is lower alkyl. The bond to the parent moiety is through the sulfonyl. "Arylsulfonyl" means an ary!-S(O2)- group. The bond to the parent moiety is through the sulfonyl.
The term "substituted" means that one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. By "stable compound' or "stable structure" is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
The term "optionally substituted" means optional substitution with the specified groups, radicals or moieties.
The term "purified", "in purified form" or "in isolated and purified form" for a compound refers to the physical state of said compound after being isolated from a synthetic process or natural source or combination thereof. Thus, the term "purified", "in purified form" or "in isolated and purified form" for a compound refers to the physical state of said compound after being obtained from a purification process or processes described herein or well known to the skilled artisan, in sufficient purity to be characterizable by standard analytical techniques described herein or well known to the skilled artisan.
It should also be noted that any carbon as well as heteroatom with unsatisfied valences in the text, schemes, examples and Tables herein is assumed to have the sufficient number of hydrogen atom(s) to satisfy the valences.
When a functional group in a compound is termed "protected", this means that the group is in modified form to preclude undesired side reactions at the protected site when the compound is subjected to a reaction. Suitable protecting groups will be recognized by those with ordinary skill in the art as well as by reference to standard textbooks such as, for example, T. W. Greene et al, Protective Groups in organic Synthesis (1991), Wiley, New York. When any variable (e.g., aryl, heterocycle, R2, etc.) occurs more than one time in any constituent or in Formula (I), (II) or (III), its definition on each occurrence is independent of its definition at every other occurrence.
As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
Prodrugs and solvates of the compounds of the invention are also contemplated herein. A discussion of prodrugs is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems (1987) t4 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, (1987) Edward B. Roche, ed., American Pharmaceutical Association and Pergamon Press. The term "prodrug" means a compound (e.g, a drug precursor) that is transformed in vivo to yield a compound of Formula (I), (II), or (III), or a pharmaceutically acceptable salt, hydrate or solvate of the compound. The transformation may occur by various mechanisms (e.g., by metabolic or chemical processes), such as, for example, through hydrolysis in blood. A discussion of the use of prodrugs is provided by T. Higuchi and W. Stella, "Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.
For example, if a compound of Formula (I), (II), or (III) or a pharmaceutically acceptable salt, hydrate or solvate of the compound contains a carboxylic acid functional group, a prodrug can comprise an ester formed by the replacement of the hydrogen atom of the acid group with a group such as, for example, (Ci-Cβ)alkyl, (C2-Ci2)alkanoyloxymethyl, 1-(alkanoyloxy)ethyl having from 4 to 9 carbon atoms, 1-methyl-1-(alkanoyloxy)-ethyl having from 5 to 10 carbon atoms, alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms, 1- (alkoxycarbonyloxy)ethyl having from 4 to 7 carbon atoms, 1-methyl-1- (alkoxycarbonyloxy)ethyl having from 5 to 8 carbon atoms, N- (alkoxycarbonyl)aminomethyl having from 3 to 9 carbon atoms, 1-(N- (alkoxycarbonyl)amino)ethyl having from 4 to 10 carbon atoms, 3-phthalidyl, 4- crotonolactonyl, gamma-butyrolacton-4-yl, di-N,N-(Ci-C2)alkylamino(C2-C3)alkyl (such as /?-dimethylaminoethyl), carbamoyl-(C1-C2)alkyl, N.N-di (Cr C2)alkylcarbamoyl-(C1-C2)alkyl and piperidino-, pyrrolidine)- or morpholino(C2- C3)alkyl, and the like.
Similarly, if a compound of Formula (I), (II), or (III) contains an alcohol functional group, a prodrug can be formed by the replacement of the hydrogen atom of the alcohol group with a group such as, for example, (Cr C6)alkanoyloxymethyl, 1-((CrC6)alkanoyloxy)ethyl, 1-methyl-1-((Cr C-6)alkanoyloxy)ethyl, (Ci-Cβjalkoxycarbonyloxymethyl, N-(Cr C6)a!koxycarbonylaminomethyl, succinoyl, (CrCβialkanoyi, α-amino(Cr C4)alkanyl, arylacyl and α-aminoacyl, or α-aminoacyl-α-aminoacyl, where each α- aminoacyl group is independently selected from the naturally occurring L-amino acids, P(O)(OH)2, -P(O)(O(CrC6)alkyl)2 or glycosyl (the radical resulting from the removal of a hydroxyl group of the hemiacetal form of a carbohydrate), and the like.
If a compound of Formula (I), (II), or (III) incorporates an amine functional group, a prodrug can be formed by the replacement of a hydrogen atom in the amine group with a group such as, for example, R-carbonyl, RO-carbonyl, NRR'- carbonyl where R and R' are each independently (CrC-io)alkyl, (C3-C7) cycloalkyl, benzyl, or R-carbonyl is a natural α-aminoacyl or natural α-aminoacyl, — C(OH)C(O)OY1 wherein Y1 is H, (CrC6)alkyl or benzyl, — C(OY2)Y3 wherein Y2 is (C1-C4) alkyl and Y3 is (C1-C6)alkyl, carboxy (Ci-Cβ)alkyl, amino(CrC4)alkyl or mono-N— or di-N,N-(CrC6)alkylaminoalkyl, — C(Y4)Y5 wherein Y4 is H or methyl and Y5 is mono-N — or di-N,N-(Ci-C6)alkylamino morpholino, piperidin-1-yl or pyrrolidin-1-yl, and the like.
One or more compounds of the invention may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the invention embrace both solvated and unsolvated forms. "Solvate" means a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. "Solvate" encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like. "Hydrate" is a solvate wherein the solvent molecule is H2O.
One or more compounds of the invention may optionally be converted to a solvate. Preparation of solvates is generally known. Thus, for example, M. Caira et al, J. Pharmaceutical ScL, 93(3), 601-611 (2004) describe the preparation of the solvates of the antifungal fluconazole in ethyl acetate as well as from water. Similar preparations of solvates, hemisolvate, hydrates and the like are described by E. C. van Tonder et al, AAPS PharmSciTech., 5(1), article 12 (2004); and A. L. Bingham et al, Chem. Commun., 603-604 (2001). A typical, non-limiting, process involves dissolving the inventive compound in desired amounts of the desired solvent (organic or water or mixtures thereof) at a higher than ambient temperature, and cooling the solution at a rate sufficient to form crystals which are then isolated by standard methods. Analytical techniques such as, for example I. R. spectroscopy, show the presence of the solvent (or water) in the crystals as a solvate (or hydrate).
"Effective amount" or "therapeutically effective amount" is meant to describe an amount of compound or a composition of the present invention effective in inhibiting the above-noted diseases and thus producing the desired therapeutic, ameliorative, inhibitory or preventative effect.
The compounds of Formula (I), (II), or (III) can form salts which are also within the scope of this invention. Reference to a compound of Formula (I), (II), or (III) herein is understood to include reference to salts thereof, unless otherwise indicated. The term "salt(s)", as employed herein, denotes acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases. In addition, when a compound of Formula (I), (II), or (III) contains both a basic moiety, such as, but not limited to a pyridine or imidazole, and an acidic moiety, such as, but not limited to a carboxylic acid, zwitterions ("inner salts") may be formed and are included within the term "salt(s)" as used herein. Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred, although other salts are also useful. Salts of the compounds of the Formula (I), (II), or (III) may be formed, for example, by reacting a compound of Formula (I), (II) or (III) with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.
Exemplary acid addition salts include acetates, ascorbates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, fumarates, hydrochlorides, hydrobromides, hydroiodides, lactates, maleates, methanesulfonates, naphthalenesulfonates, nitrates, oxalates, phosphates, propionates, salicylates, succinates, sulfates, tartarates, thiocyanates, toluenesulfonates (also known as tosylates,) and the like. Additionally, acids which are generally considered suitable for the formation of pharmaceutically useful salts from basic pharmaceutical compounds are discussed, for example, by P. Stahl et al, Camille G. (eds.) Handbook of Pharmaceutical Salts. Properties, Selection and Use. (2002) Zurich: Wiley- VCH; S. Berge et al, Journal of Pharmaceutical Sciences (1977) 66(1) 1-19; P. Gould, International J. of Pharmaceutics (1986) 33 201-217; Anderson et al, The Practice of Medicinal Chemistry (1996), Academic Press, New York; and in The Orange Book (Food & Drug Administration, Washington, D. C. on their website). These disclosures are incorporated herein by reference thereto.
Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as dicyclohexylamines, t-butyl amines, and salts with amino acids such as arginine, lysine and the like. Basic nitrogen-containing groups may be quartemized with agents such as lower alkyl halides (e.g. methyl, ethyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g. dimethyl, diethyl, and dibutyl sulfates), long chain halides (e.g. decyl, lauryl, and stearyl chlorides, bromides and iodides), aralkyl halides (e.g. benzyl and phenethyl bromides), and others.
All such acid salts and base salts are intended to be pharmaceutically acceptable salts within the scope of the invention and all acid and base salts are considered equivalent to the free forms of the corresponding compounds for purposes of the invention.
Pharmaceutically acceptable esters of the present compounds include the following groups: (1) carboxylic acid esters obtained by esterification of the hydroxy groups, in which the non-carbonyl moiety of the carboxylic acid portion of the ester grouping is selected from straight or branched chain alkyl (for example, acetyl, n-propyl, t-butyl, or n-butyl), alkoxyalkyl (for example, methoxymethyl), aralkyl (for example, benzyl), aryloxyalkyl (for example, phenoxymethyl), aryl (for example, phenyl optionally substituted with, for example, halogen, C-ι_4alkyl, or Ci- 4alkoxy or amino); (2) sulfonate esters, such as alkyl- or aralkylsulfonyl (for example, methanesulfonyl); (3) amino acid esters (for example, L-valyl or L- isoleucyl); (4) phosphonate esters and (5) mono-, di- or triphosphate esters. The phosphate esters may be further esterified by, for example, a C1^o alcohol or reactive derivative thereof, or by a 2,3-di
Figure imgf000039_0001
glycerol.
Compounds of Formula (I), (II), and (III) and salts, solvates, esters and prodrugs thereof, may exist in their tautomeric form (for example, as an amide or imino ether). All such tautomeric forms are contemplated herein as part of the present invention.
The compounds of Formula (I), (II), or (III) may contain asymmetric or chiral centers, and, therefore, exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of Formula (I), (II), or (III) as well as mixtures thereof, including racemic mixtures, form part of the present invention. In addition, the present invention embraces all geometric and positional isomers. For example, if a compound of Formula (I), (II), or (III) incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the invention.
Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as, for example, by chromatography and/or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. Also, some of the compounds of Formula (I), (II), or (III) may be atropisomers (e.g., substituted biaryls) and are considered as part of this invention. Enantiomers can also be separated by use of chiral HPLC column.
It is also possible that the compounds of Formula (I), (II), or (III) may exist in different tautomeric forms, and all such forms are embraced within the scope of the invention. Also, for example, all keto-enol and imine-enamine forms of the compounds are included in the invention.
All stereoisomers (for example, geometric isomers, optical isomers and the like) of the present compounds (including those of the salts, solvates, esters and prodrugs of the compounds as well as the salts, solvates and esters of the prodrugs), such as those which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this invention, as are positional isomers (such as, for example, 4-pyridyl and 3-pyridyl). (For example, if a compound of Formula (I), (II), or (III) incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the invention. Also, for example, all keto-enol and imine-enamine forms of the compounds are included in the invention.) Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers. The chiral centers of the present invention can have the S or R configuration as defined by the IUPAC 1974 Recommendations. The use of the terms "salt", "solvate", "ester", "prodrug" and the like, is intended to equally apply to the salt, solvate, ester and prodrug of enantiomers, stereoisomers, rotamers, tautomers, positional isomers, racemates or prodrugs of the inventive compounds.
The present invention also embraces isotopically-labelled compounds of the present invention which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as 2H, 3H, 13C, 14C, 15N, 18O1 170, 31P, 32P, 35S, 18F, and 36CI, respectively.
Certain isotopically-labelled compounds of Formula (I), (II), or (III) (e.g., those labeled with 3H and 14C) are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e., 3H) and carbon-14 (i.e., 14C) isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., 2H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances, lsotopically labelled compounds of Formula (I), (II), or (III) can generally be prepared by following procedures analogous to those disclosed in the Schemes and/or in the Examples hereinbelow, by substituting an appropriate isotopically labelled reagent for a non-isotopically labelled reagent.
Polymorphic forms of the compounds of Formula (I), (II), or (III), and of the salts, solvates, esters and prodrugs of the compounds of Formula (I), (II), or (III), are intended to be included in the present invention.
When a variable appears more than once in the structural formula, for example R3 or R5, the identity of each variable appearing more than once may be independently selected from the definition for that variable.
The compounds of the present invention can have pharmacological properties, for example the compounds of Formula I, Il or III can be inhibitors of TACE (TNF-α) and/or MMP activity. The compounds of Formula I, Il or III can have anti-inflammatory activity and/or immunomodulatory activity and can be useful in the treatment of diseases including but not limited to septic shock, haemodynamic shock, sepsis syndrome, post ischaemic reperfusion injury, malaria, mycobacterial infection, meningitis, psoriasis, congestive heart failure, fibrotic diseases, cachexia, graft rejection, cancers such as cutaneous T-cell lymphoma, diseases involving angiogenesis, autoimmune diseases, skin inflammatory diseases, inflammatory bowel diseases such as Crohn's disease and colitis, osteo and rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, adult Still's disease, ureitis, Wegener's granulomatosis, Behcehe disease, Sjogren's syndrome, sarcoidosis, polymyositis, dermatomyositis, multiple sclerosis, radiation damage, hyperoxic alveolar injury, periodontal disease, HIV, non-insulin dependent diabetes mellitus, systemic lupus erythematosus, glaucoma, sarcoidosis, idiopathic pulmonary fibrosis, bronchopulmonary dysplasia, retinal disease, scleroderma, osteoporosis, renal ischemia, myocardial infarction, cerebral stroke, cerebral ischemia, nephritis, hepatitis, glomerulonephritis, cryptogenic fibrosing aveolitis, psoriasis, transplant rejection, atopic dermatitis, vasculitis, allergy, seasonal allergic rhinitis, reversible airway obstruction, adult respiratory distress syndrome, asthma, chronic obstructive pulmonary disease (COPD) and/or bronchitis. It is contemplated that a compound of this invention may be useful in treating one or more of the diseases listed.
Additionally, a compound of the present invention may be co-administered or used in combination with disease-modifying antirheumatic drugs (DMARDS) such as methotrexate, azathioprine, leflunomide, pencillinamine, gold salts, mycophenolate mofetil, cyclophosphamide and other similar drugs. They may also be co-administered with or used in combination with NSAIDS such as piroxicam, naproxen, indomethacin, ibuprofen and the like; COX-2 selective inhibitors such as Vioxx® and Celebrex®; immunosuppressives such as steroids, cyclosporin, Tacrolimus, rapamycin and the like; biological response modifiers (BRMs) such as Enbrel®, Remicade®, IL-1 antagonists, anti-CD40, anti-CD28, IL-10, anti-adhesion molecules and the like; and other anti-inflammatory agents such as p38 kinase inhibitors, PDE4 inhibitors, other chemically different TACE inhibitors, chemokine receptor antagonists, Thalidomide and other small molecule inhibitors of pro-inflammatory cytokine production.
Also, a compound of the present invention may be co-administered or used in combination with an H1 antagonist for the treatment of seasonal allergic rhinitis and/or asthma. Suitable H1 antagonists may be, for example, Claritin®, Clarinex®, Allegra®, or Zyrtec®.
In another aspect, the invention provides a method for treating rheumatoid arthritis comprising administering a compound of the formula I, Il or III in combination with compound selected from the class consisting of a COX-2 inhibitor e.g. Celebrex® or Vioxx®; a COX-1 inhibitor e.g. Feldene®; an immunosuppressive e.g. methotrexate or cyclosporin; a steroid e.g. β-methasone; and anti-TNF-α compound, e.g. Enbrel® or Remicade®; a PDE IV inhibitor, or other classes of compounds indicated for the treatment of rheumatoid arthritis.
In another aspect, the invention provides a method for treating multiple sclerosis comprising administering a compound of the formula I, Il or III in combination with a compound selected from the group consisting of Avonex®, Betaseron, Copaxone or other compounds indicated for the treatment of multiple sclerosis.
TACE activity is determined by a kinetic assay measuring the rate of increase in fluorescent intensity generated by TACE catalyzed cleavage of an internally quenched peptide substrate (SPDL-3). The purified catalytic domain of recombinant human TACE (rhTACEc, Residue 215 to 477 with two mutation (S266A and N452Q) and a 6xHis tail) is used in the assay. It is purified from the baculovirus/Hi5 cells expression system using affinity chromatography. The substrate SPDL-3 is an internally quenched peptide (MCA-Pro-Leu-Ala-Gln-Ala- Val-Arg-Ser-Ser-Ser-Dpa-Arg-NH2), with its sequence derived from the pro-TNFα cleavage site. MCA is (7-Methoxycoumarin-4-yl)acetyl. Dpa is N-3-(2,4- Dinitrophenyl)-L-2,3-diaminopropionyl.
A 50 μl assay mixture contains 20 mM HEPES, pH 7.3, 5 mM CaCI2, 100 μM ZnCI2, 2 % DMSO, 0.04% Methylcellulose, 30 μM SPDL-3, 70 pM rhTACEc and a test compound. RhTACEc is pre-incubated with the testing compound for 90 min. at 25 0C. Reaction is started by addition of the substrate. The fluorescent intensity (excitation at 320 nm, emission at 405 nm) was measured every 45 seconds for 30 min. using a fluorospectrometer (GEMINI XS, Molecular Devices). Rate of enzymatic reaction is shown as Units per second. Effect of a test compound is shown as % of TACE activity in the absence of the compound.
Useful compounds for TACE inhibitory activity can exhibit Ki values of less than about 1000 nm, preferably about 0.01 nm to about 1000 nm, more preferably about 0.1 nm to about 100 nm, more preferably about 0.1 to about 15 nm, and most preferably less that about 15 nm. The TACE inhibitory activity (Ki values) of some representative compounds of the present invention are listed in the "EXAMPLES" section hereinbelow.
The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients that are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the technique described in the U.S. Pat. Nos. 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for controlled release.
Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredients is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or a soft gelatin capsules where in the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.
Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethyl-cellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example, heptadecaethylene-oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example, polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example, ethyl or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.
Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example, arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example, beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, e.g., sweetening, flavoring and coloring agents, may also be present.
The pharmaceutical compositions of the invention may also be in the form of an oil-in-water emulsions. The oily phase may be a vegetable oil, e.g., olive oil or arachis oil, or a mineral oil, e.g., liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring phosphatides, e.g., soy beans, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example, sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, e.g., polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavoring agents.
Syrups and elixirs may be formulated with sweetening agents, for example, glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, e.g., as a solution in 1 ,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.
Compounds of the invention may also be administered in the form of suppositories for rectal administration of the drug. The compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.
For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing the compound of the invention are employed. (For purposes of this application, topical application shall include mouthwashes and gargles.)
The compounds for the present invention can be administered in the intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in the art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen. Compounds of the present invention may also be delivered as a suppository employing bases such as cocoa butter, glycerinated gelatin, hydrogenated vegetable oils, mixtures of polyethylene glycols of various molecular weights and fatty acid esters of polyethylene glycol.
The dosage regimen utilizing the compounds of the present invention is selected in accordance with a variety of factors including type, species, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound thereof employed. A physician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the drug required to prevent, counter, arrest or reverse the progress of the condition. Optimal precision in achieving concentration of drug within the range that yields efficacy without toxicity requires a regimen based on the kinetics of the drug's availability to target sites. This involves a consideration of the distribution, equilibrium, and elimination of a drug. Preferably, doses of the compound of Formula I, Il or III useful in the method of the present invention range from 0.01 to 1000 mg per day. Most preferably, dosages range from 0.1 to 500 mg/day. For oral administration, the compositions are preferably provided in the form of tablets containing 0.01 to 1000 milligrams of the active ingredient, particularly 0.01 , 0.05, 0.1 , 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100 and 500 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. An effective amount of the drug is ordinarily supplied at a dosage level of from about 0.0002 mg/kg to about 50 mg/kg of body weight per day. The range is more particularly from about 0.001 mg/kg to 1 mg/kg of body weight per day.
Advantageously, the active agent of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in dividend doses of two, three or four time daily.
The amount of active ingredient that may be combined with the carrier materials to produce single dosage form will vary depending upon the host treated and the particular mode of administration.
It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the age, body weight, general health, sex, diet, time of administration, route or administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.
The compounds of the invention may be produced by processes known to those skilled in the art and as shown in the following reaction schemes and in the preparations and examples described below.
EXAMPLES
The following abbreviations are used in the procedures and schemes: dichloromethane (DCM); tetrabutylammonium bromide (TBAB); Benzyl (Bn); acetonitrile (MeCN); ethyl acetate(EtOAc); Tetrahydrofuran (THF); Trifluoroacetic acid (TFA); 1-hydroxy-7-aza-benzotriazole (HOAt); 1- hydroxylbenzotriazole(HOAt); N-methylmorpholine (NMM); 1-(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI); diisopropylethyl amine (DIEA); 1-hydroxybenzotriazole (HOBt); Dimethoxyethane (DME). [1- (chloromethyl)-4-fluoro-1 ,4-diazoniabicyclo[2.2.2] octane bis(tetrafluoroborate)] (Selectfluor); 4-N,N-dimethylaminopyridine (DMAP); 1 ,8-diazabicyclo[5,4,0]undec- 7-ene (DBU);
Saturated (sat.); anhydrous, (anhyd); room temperature (rt); hour (h); Minutes (Min), Retention Time (Rt); molecular weight (MW); milliliter (ml_); gram (g). milligram (mg); equivalent (eq).
All NMR data were collected on 400 MHz NMR spectrometers unless otherwise indicated. LC-Electrospray-Mass spectroscopy with a C-18 column and 5% to 95% MeCN in water as the mobile phase was used to determine the molecular mass and retention time.
The compounds in the invention may be produced by processes known to those skilled in the art and as shown in the following reaction schemes and in the preparations and examples described below. Table 1 contains the compounds with retention time/observed MW and/or NMR data. The compounds of Table 1 can be obtained using synthetic methods similar to those below as listed in the last column of Table 1 using appropriate reagents known to those skilled in the art. Method A
Figure imgf000049_0001
A11 A12
Method A; Step 1
To a suspension of NaH (0.76 g, 31.70 mmol) (washed with pentane 3x and dried under vacuum) in THF (50 ml_) was added A1 (5.0 mL, 25 mmol) followed by 4-benzyloxy benzyl chloride (5.75g, 25 mmol) and tetrabutylammonium iodide (0.500 g). The reaction was stirred at room temperature for 72 hours. The reaction was quenched with H2O and diluted with EtOAc. The organic phase was removed and the aqueous layer was extracted with EtOAc (2x). The combined organics were washed with brine (1x), dried (Na2SO4), filtered, and concentrated. The residue was purified by silica gel chromatography (eluting 0% to 100% EtOAc/hexanes) to furnish A2 (1.0 g, 2.4 mmol, 10% yield). MS m/e: 421.1 (M+H).
Method A, Step 2. To a suspension of NaH (0.009 g, 0.38 mmol) in THF (0.5 mL) at room temperature was added A2 (0.12 g, 0.28 mmol) dropwise as a solution in THF (0.5 ml_). The reaction was stirred at room temperature for 15 minutes and A31 (0.054 g, 0.33 mmol) was added as a solution in THF (0.5 mL). The resulting mixture was stirred 18 hours. The reaction was quenched with H2O and diluted with EtOAc. The organic phase was separated, and the aqueous phase was extracted with EtOAc (2x). The combined organics were washed with brine (1x), dried (Na2SO4), filtered, and concentrated. The residue was purified by silica gel chromatography (eluting 0% to 50 % EtOAc/hexanes) to furnish A4 (0.039 g, 0.091 mmol, 32% yield) and A5 (0.042 g, 0.98 mmol, 34% yield). For A4: MS m/e: 431.1 (M+H). For 5: MS m/e: 431.1 (M+H).
Method A Step 3,
To a solution of A4 (0.245 g, 0.57 mmol) and N-(methoxymethyl)-N-(trimethyl- silylmethyl) benzylamine (0.437 mL, 1.71 mmol) in toluene (5 mL) cooled to 0 °C was added TFA (3 drops). The reaction was stirred for 15 minutes at 0 °C, and then quenched with 7 N NH3/MeOH (1 mL). The reaction was concentrated, and the residue was purified by reverse phase HPLC (eluting 10:90 to 95:5 CH3CN/H2O (0.1 % HCO2H)) to furnish A6 (0.29 g, 0.51 mmol, 90% yield) as a white solid. MS m/e: 564.1 (M+H).
Method A Step 4.
A solution of A6 (0.069 g, 0.12 mmol) and 10% Pd/C (25 mg) in MeOH (2 mL)/CH2CI2 (1 mL) was stirred at room temperature under an atmosphere of hydrogen for 5 hours. The reaction was filtered through a pad of celite, and the liquid was concentrated. To a solution of the crude mixture in THF (1.5 mL)/H2O (0.7 mL) was added NaHCO3 (0.036 g, 0.43 mmol) and (BOC)2O (0.036 g, 0.16 mmol). The reaction was stirred for 18 hours at room temperature. The reaction was diluted with Et2O, and the organic layer was removed. The aqueous phase was acidified with sat. NH4CI to about neutral pH and was extracted with EtOAc
1 Bishop, J. E.; O'Connell, J. F.; Rapoport, H. J. Org. Chem. 1991, 56, 5079 (3x). The combined organics were dried (Na2SO4), filtered, and concentrated to provide A7 (0.027 g, 0.69 mmol, 57% yield over 2 steps). MS m/e: 394.1 (M+H).
Method A Step 5.
To a solution of A7 (0.027 g, 0.069 mmol) in CH2CI2 (1 ml_) cooled to 0 0C was added NMM (0.023 ml_, 0.21 mmol), EDCI (0.028 g, 0.15 mmol), and HOAt (0.018 g, 0.13 mmol). This mixture was stirred for 20 minutes and then O-p- Methoxybenzyl-N-2,4-dimethoxybenzylhydroxylamine (0.043 g, 0.14 mmol) was added. The resulting mixture was stirred for 16 hours gradually warming to room temperature. The reaction was quenched with H2O and diluted with EtOAc. The organic layer was separated, and the aqueous layer extracted with EtOAc (3x). The combined organics were washed with brine (2x), dried (Na2SO4), filtered, and concentrated. The residue was purified by silica gel chromatography (eluting 0% to 100% EtOAc/hexanes) to furnish A9 (0.032 g, 0.047 mmol, 68% yield). MS m/e: 679.2 (M+H).
Method A Step 6.
To a solution of A9 (0.032 g, 0.047 mmol) in CH2CI2 (1 ml_) was added K2CO3 (0.093 g, 0.67 mmol), 2-phenylquinolin-4-yl-methylchloride HCI salt (0.021 g, 0.073 mmol), and tetrabutylammonium iodide (0.005 g, 0.013 mmol). The resulting mixture was stirred for 72 hours at room temperature. At this time, the reaction was quenched with H2O and diluted with EtOAc. The organic phase was removed, and the aqueous layer was extracted with EtOAc (2x). The combined organics were washed with brine (1x), dried (Na2SO4), filtered, and concentrated. The residue was purified by silica gel chromatography (eluting 0% to 80% EtOAc/hexanes) to furnish A11 (0.020 g, 0.022 mmol, 48% yield). MS m/e: 896.2 (M+H).
Method A Step 7.
To a solution of A11 (0.016 g, 0.018 mmol) in CH2CI2 (0.7 mL) at room temperature was added Et3SiH (0.012 mL, 0.54 mmol) followed by TFA (0.3 mL). The reaction was stirred for 168 hours, and the reaction was concentrated. The residue was purified by reverse phase HPLC (eluting 5:95 to 95:5 CH3CN/H2O (0.1 % HCO2H)) to provide A12 (0.006 g, 0.011 mmol, 67% yield) as a white solid. MS m/e: 526.1 (M+H).
Method B
Figure imgf000052_0001
Method B, Step 1.
A mixture of B1 (1.28 g, 6.89 mmol), compound B2 (2.0 g, 6.89 mmol), Cs2CO3 (4.50 g, 13.8 mmol), and DMF (30 ml_) was stirred at room temperature for 16 hours. Saturated aqueous NaHCO3 (100 ml_) was added and the aqueous phase was extracted with EtOAc (150 ml_). The organic phase was washed with brine (50 ml_), dried over Na2SO4, filtered, and concentrated to give compound B3 (3-1 g).
Method B, Step 2
To a solution of compound B3 (2.5 g, 85%, 6.29 mmol) in THF/water (4:1 , 20 ml_) was added LiOH (300 mg, 12.5 mmol). The solution was stirred at 35 0C for 2 hours. After cooled to room temperature, it was poured into 1N HCI solution with stirring. A white solid was filtered, washed with water and EtOAc, dried at 45 0C for 8 hours to give compound B4 (2.0 g, 83%).
Method B, Step 3
The solution of compound B4 (1.2 g, 3.1 mmol) and thionyl chloride (6 mL) was heated to 80 0C for three hours. After cooling to room temperature, thionyl chloride was removed with a cold NaOH solution in the solvent receiver. The residue was dried under vacuum for three days to give compound B5 which was used without further purification.
Method B, Step 4
To a solution of (4-methoxy-phenylimino)-acetic acid ethyl ester (Niwa, Y.; Shimizu, M. Journal of the American Chemical Society 2003, 125(13), 3720-3721. 78 mg, 0.40 mmol) and TEA (0.167 mL, 1.20 mmol) in dry CH2CI2 (0.5 mL) was added compound B5 (176 mg, 0.40 mmol, in 1 mL CH2CI2). The solution was heated to 37 0C to 40 0C for 16 hours. After cooled to room temperature, the solution was subjected to silica gel chromatography (Heaxne/EtOAc 3:1 ) to give compound B6 (7.2 mg, 3.1 %).
Method B, Step 5
To a cold solution of compound B6 (27 mg, 0.047 mmol) in CH3CN (1 mL) was added CAN (77 mg, 0.14 mmol, in 0.5 mL water) at 0 0C followed by another addition of CAN (77 mg, 0.14 mmol, in 0.5 mL water in 15 minutes, more CAN) The solution was stirred at 0 0C for an additional 15 minutes before a saturated aqueous Na2SO3 solution was added and the aqueous phase was extracted with EtOAc (10 mL) three times. The organic phases were washed with brine (10 mL), dried over Na2SO4, filtered, and concentrated by rotary evaporator. The product was isolated by prep TLC (CH2CI2/MeOH/NH3 25:1 :0.1 ) to give compound B7 (5.0 mg).
Method B, Step 6 A solution of compound B7 (5.0 mg), hydroxyamine hydrochloride (15 mg), and DBU (36 mg) in MeOH (0.5 mL) was sonicated for 30 minutes. Solvent was removed by rotary evaporator and the crude product B8 was purified by reverse phase HPLC (CH3CN/water/0.1 % HCO2H) to give compound 8 (1.0 mg). MS 454.1 [M+H]+.
Method C
Figure imgf000054_0001
Cl Cl C3 C4 C5
Method C, Step l.
A solution of Compound C1 (2.14 g, 17.23 mmol), 4-chloromethyl-2-phenyl- quinoline HCI (5.0 g, 17.23 mmol), Cs2CO3 (11.8 g, 36.2 mmol), and dry DMF (60 mL) was stirred at room temperature for 20 hours. A saturated aqueous NaHCO3 solution was added and the aqueous phase was extracted with EtOAc (300 mL). The organic phase was washed with water (100 mL) and brine (100 mL), dried over Na2SO4, filtered, concentrated by rotary evaporator, and dried under vacuum overnight to give [4-(2-phenyl-quinolin-4-ylmethoxy)~phenyl]-methanol (5.81 g, 99%). [4-(2-Phenyl-quinolin-4-ylmethoxy)-phenyl]-methanol (4.0 g, 11.73 mmol) was dissolved in dry CH2CI2 (60 mL) and was cooled to 0 0C. before PBr3 (1.1 mL, 11.73 mmol, in 5 mL CH2CI2) was added. The solution was stirred overnight at room temperature. The solution was poured into a cold aqueous NaHCO3 solution (250 mL) with stirring. The aqueous phase was extracted with EtOAc (150 mL) four times. The organic phase was washed with brine (50 mL), dried over Na2SO4, filtered, and concentrated by rotary evaporator to give compound C2 (4.3 g, 91%). Method C, Step 2.
To a solution of 1-(tert-butyl-dimethyl-silanyl)-4-oxo-azetidine~2~carboxylic acid (Baldwin, J. E.; Adlington, R. M.; Gollins, D. W.; Schofield, C. J. Tetrahedron 1990, 46(13-14), 4733-48, 500 mg, 2.18 mmol) in dry THF (10 ml_) was added LDA (2M, 2.7 ml_, 5.45 mmol) at 0 0C and the reaction was stirred for 15 minutes before the solution was cooled to -20 0C and compound C2 (1.06 gram, 2.62 mmol, in 3 ml_ THF) was added. The solution was gradually warmed up to 0 0C and stirred at 0 0C for an hour. A cold HCI solution (0.4 M) was added and the aqueous phase was extracted with EtOAc (100 ml_) twice. The organic phase was dried over Na2SO4, filtered, and concentrated by rotary evaporator. The product C3 was isolated by silica gel chromatography (CH2CI2/MeOH/HCO2H: 40:1 :0.1 to 20:1 :0.1 ) to give compound 3 (700 mg, 58%).
Method C, Step 3.
A solution of compound C3 (41 mg, 0.074 mmol), TrONH2 (41 mg, 0.15 mmol), EDCI (29 mg, 0.15 mmol), HOBT (20 mg, 0.15 mmol), and NMM (20 mg, 0.2 mmol) in DMF (1 ml_) was stirred at room temperature for 16 hours. Water was added and the aqueous phase was extracted with EtOAc. The organic phase was washed with brine, dried over Na2SO4, filtered, and concentrated by rotary evaporator. The product was isolated by prep silica gel TLC (CH2CI2/MeOH: 40:1) to give compound C4 (17 mg).
Method C, Step 4.
To a solution of compound C4 (17 mg) in CH2CI2 was added Et3SiH (two drops) and TFA (two drops) at room temperature. Three minutes later, the solvent was removed by rotary evaporator. The product was isolated by prep silica gel TLC (CH2CI2/MeOH 10:1) twice to give compound C5 (4.2 mg). MS: 454.1 [M+H]+.
Method D
Figure imgf000056_0001
Dl D2
Method D, Step 1
To a solution of compound D1 (34 mg, 0.06 mmol) in THF was added TBAF (1 M in THF, 0.07 m!_, 0.07 mmol) at 0 0C. Five minutes later, the solvent was removed by rotary evaporator and the product was isolated by silica gel chromatography (CH2Cl2/MeOH/HCO2H: 10:1 :0.1 ) to give compound D2 (14.0 mg). MS 439.1 [M+H]+.
Example E
Figure imgf000056_0002
El E2 E3
Method E, Step 1
To a solution of compound E1 (60 mg, 0.11 mmol) in dry THF (1 ml_) was added LDA (2M, 0.16 ml_, 0.33 mmol) at -30 0C. The solution was warmed up to 0 0C in 5 minutes and stirred at 0 0C for 10 minutes. It was recooled to -40 0C and methyl cyano formate (0.026 mL, 0.33 mmol) was added. The solution was gradually warmed up to 0 0C in two hours. 0.4N HCI solution was added. The aqueous phase was extracted with EtOAc (10 mL). The organic phase was dried over Na2SO4, filtered, and concentrated by rotary evaporator. The crude product was purified by silica gel chromatography (CH2CI2ZMeOHZHCO2H: 40:1 :0.1 to 20:1 :0.1) to give compound E2 (35 mg).
Compound E3 was prepared in a similar manner as described in Method C. MS: 512.1 [M+H]+.
Method F
Figure imgf000057_0001
Step 4
Figure imgf000057_0002
F6 F5
Method F; Step 1
Compound F2 is generated using procedures similar to Method A Step 1. Method F; Step 2.
Compound F3 is generated using procedures similar to method A step 2 and 3. Method F; Step 3.
Compound F4 is generated using a literature procedure (JACS, 123, 2001 , 10770). To a toluene solution of 2-phenylquinolin-4-yl-methanol (0.3 mmol) is added F3 (0.150 mmol), Cs2CO3 (0.375 mmol), palladium acetate (12 mg) and 1 ,1 '-binaphthyl-2-yl-di-t-butyl phosphine (30 mg). The reaction mixture is flushed with Nitrogen followed by heating at 110 0C overnight. The reaction mixture is then cooled to r.t. before it is chromatographed via a silica gel column to give F4. Method F Step 4,
To a DCM solution of F4 is added 1-chloroethyl chloroformate (2 eq) and proton sponge (3 eq). After the reaction was stirred overnight, it is quenched with aq. potassium bicarbonate until the mixture pH reaches 9. To the mixture is added Boc anhydride and the reaction mixture is stirred overnight before it is extracted with DCM. The organic solution is dried and the solvent evaporated. The residue is chromatographed via a silica gel column to give the desired product F5.
Method F Step 5.
Compound F5 is obtained using procedures similar to Method A, Step 4, 5 and 7.
In the table below, those compounds having a Ki value of less than 20 nM (<20 nM) are designated with letter "A"; those with a Ki value of from 20 to less than 100 nM (10 - <100 nM) are designated with letter "B"; those with a Ki value of from 100 to 1000 nM are designated with letter "C"; and those with a Ki value of more than 1000 nM (>1000 nM) are designated with letter "D".
Figure imgf000059_0001
Specific TACE inhibitory activity (Ki values) of some representative compounds of the present invention are set forth below.
Figure imgf000060_0001
It will be appreciated by those skilled in the art that changes could be made to the embodiments described above without departing from the broad inventive concept thereof. It is understood, therefore, that this invention is not limited to the particular embodiments disclosed, but it is intended to cover modifications that are within the spirit and scope of the invention, as defined by the appended claims.

Claims

THEREFORE, WE CLAIM:
1. A compound represented by Formula (I):
Figure imgf000061_0001
or a pharmaceutically acceptable salt, solvate or ester thereof, wherein:
M, together with the two carbon atoms to which it is shown attached in formula (I) is 4-7 membered hetereocyclyl or heterocyclenyl comprising 0-3 carbonyl groups,
0-3 double bonds, and 1-3 heteroatoms selected from O, N, and S, wherein said
4-7 membered hetereocyclyl or heterocyclenyl can, in addition to the four substituents V, R2, T, and -(W)n-X-U-R1 as set forth in formula (I), be further optionally substituted with R21;
T is selected from the group consisting of H, alkyl, R21 -substituted alkyl, cycloalkyl, aryl, heteroaryl, hetereocyclyl, arylalkyl, heteroarylalkyl, -OR3, -C(O)R4, -C(O)OR3,
-C(O)NR24R25, -C(O)NR24OR3, -C(O)SR3, -NR24R25, -NR25C(O)R4, -NR25C(O)OR3,
-NR25C(O)NR24R25, -NR25C(O)NR24OR3, -SR3, -N(R24)S(O)2R25, -S(O)xNR24R25, -
S(O)xNR25OR3, -CN, -P(O)(R24XOR24), -P(O)(OR24)(OR24), -C(R4)(=N(OR3)), -
C(O)-N(R31)CH(R32)-C(O)NR24R25 and
-C(O)N(R31)CH(R32)-C(O)-NR25OR3, wherein each of the cycloalkyl, aryl, heteroaryl, hetereocyclyl, arylalkyl and heteroarylalkyl groups of T is unsubstituted or optionally independently substituted with one to six R20 moieties which can be the same or different, each R20 moiety being independently selected from the group of R20 moieties below;
V is selected from the group consisting of alkyl, R21-substituted alkyl, cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl, heteroaryl, -OR3, -C(O)R4, -(CR23R24)ni C(O)OR3, -C(O)NR24R25, -(CR23R24)niC(O)NR25OR3, -C(O)SR3, -C(R23)(R24)SH, -NR24R25, -NR25C(O)R4, -NR25C(O)OR3, -NR25C(O)NR24R25, -NR25C(O)NR24OR3, -SR3, -S(O)xNR24R25, -S(O)xNR25OR3, -CN, -P(O)(R25)(OR24), -P(O)(OR24)(OR24), -C(R4X=N(OR3)), -C(O)-N(R31)CH(R32)-C(O)NR24R25 and -C(O)N(R31)CH(R32)-C(O)-NR25OR3, wherein each of the cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl and heteroaryl groups of V is unsubstituted or optionally independently substituted with one to three R20 moieties which can be the same or different, each R20 moiety being independently selected from the group of R20moieties below;
W is selected from the group consisting of
Figure imgf000062_0001
a covalent bond, -(C(R3)(R4))n2-, -O-, -S-, -N(R24)-, and -N(Z)-;
X is selected from the group consisting of alkyl, cylcloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl, heteroaryl and -C^C- 1 wherein each of the alkyl, cylcloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl, and heteroaryl groups of X is unsubstituted or optionally independently substituted with one to four selected R20 moieties which can be the same or different, each R20 moiety being independently selected from the group of R20 moieties below,
U is selected from the group consisting of a covalent bond,
-(C(R3)(R4))p-, -Y-(C(R3)(R4))q-, -(C(R3)(R4))t-Y-, -N(R3)(Z)-Q-, -Q-N(R3)(Z)- and -Y-;
Q is selected from the group consisting of -S(O)-, -S(O)2-, -C(O)-, and - C(O)NR4-;
Y is selected from the group consisting of -O-, -S(O)x-, -N(Z)-, -N(R4)(Z); - C(O)-, -OC(O)-, -C(O)N(R24)-, -N(R24)C(O)N(R25)-, -N(R24)S(O)-, -N(R24)S(O)2-, -S(O)N(R24)-, and -S(O)2N(R24)-;
Z is selected from the group consisting of -R3, -C(O)R3, -S(O)xR3 and -C(O)NR3R4; n is O to 2; n1 is O to 2; n2 is 1 to 2; p is 1 to 4; q is 1 to 4; t is 1 to 4; v is 1 to 3; x is 0 to 2; y is 0 to 3;
R1 is selected from the group consisting of alkyl, R21 -substituted alkyl, cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl, heteroaryl, -C-^≡CR and -CR3=CR4R5, wherein each of the alkyl, cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl and heteroaryl groups of R1 is unsubstituted or optionally independently substituted with one to six R20 moieties which can be the same or different, each R20 moiety being independently selected from the group of R20 moieties below, each of R2, R4 and R5 is the same or different and each is independently selected from the group consisting of H, halo, alkyl, R22-substituted alkyl, cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl, heteroaryl, -OR6, -C(O)R7, -C(O)OR6, -NR24R25, -NR24C(O)R25, -N(=C-O-NR24R25), and -NR24S(O)2R25, wherein each of the cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl and heteroaryl groups of R2, R4 and R5 is unsubstituted or optionally independently substituted with one to six alkyl, R22-substituted alkyl or R22 moieties which can be the same or different, each R22 moiety being independently selected from the group of R22 moieties below; each R3 is the same or different and is independently selected from the group consisting of H, alkyl, R22-substituted alkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl, heteroaryl, -OR6, -C(O)R7, -C(O)OR6, -NR24R25, -NR24C(O)R25, -N(=C-O-NR24R25) and -NR24S(O)2R25, wherein each of the cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl and heteroaryl groups of R3 is unsubstituted or optionally independently substituted with one to four alkyl, R22-substituted alkyl or R22 moieties which can be the same or different, each R22 moiety being independently selected from the group of R22 moieties below; each R6 is independently selected from the group consisting of H, alkyl and -OCF3; each R7 is independently selected from the group consisting of H, alkyl, heteroaryl and -CF3; each R20 is independently selected from the group consisting of: alkyl, R21- substituted alkyl, -OR3, halo, (-0), -CN, -NO2, -NR24R25, -C(O)R3, -C(O)OR3, - C(O)NR24R25, -S(O)xNR24R25, -S(O)xR5, -CF3, -OCF3, -CF2CF3, -CH(=NOH), - C(=NOH)R3, aryl, heteroaryl, cycloalkyl, hetereocyclyl, -N(R25)S(O)XR5, - N(R25)C(O)R5, and -N(R25)C(O)NR24R25, wherein each of the aryl, heteroaryl, cycloalkyl and hetereocyclyl groups of R20 is unsubstituted or optionally independently substituted with one to four R22 moieties which can be the same or different, each R22 moiety being independently selected from the group of R22 moieties below, or two R20 groups taken together with the carbon to which both R20 groups
are attached i iss
R21 is one to three substituents independently selected from the group consisting of: -OR3, halo, -CN, -NO2, -NR24R25, -C(O)R3, -C(O)OR3, -C(O)NR24R25, -S(O)xNR24R25, -SOxR5, -CF3, -OCF3, -CF2CF3, -C(=NOH)R3, R23- substituted alkyl, aryl, heteroaryl, cycloalkyl, hetereocyclyl, -N(R25)S(O)XR5, - N(R25)C(O)R5, and -N(R25)C(O)NR24R25; wherein each of the aryl, heteroaryl, cycloalkyl, and hetereocyclyl groups of R21 is unsubstituted or optionally independently substituted with one to four R23 moieties which can be the same or different, each R23 moiety being independently selected from the group of R23 moieties below, or two R21 groups taken together with the carbon to which both R21 groups
are attached is
Figure imgf000065_0001
each R22 is independently selected from the group consisting of: halo, alkynyl, aryl, heteroaryl, -OR24, -(C1-C6 alkyl)-OR24, -CN, -NO2, -NR24R25, -C(O)R23, -C(O)OR23, -C(O)NR24R25, -S(O)xNR24R25, -S(O)xR23, - CF3, -OCF3, -CF2CF3, -C(=NOH)R23, -N(R24)S(O)XR25, -N(R24)C(O)R25, and - N(R24)C(O)NR24R25, or two R22 groups taken together with the carbon to which both R22 groups
are attached is
Figure imgf000065_0002
each R23 is independently selected from the group consisting of H, hydroxyl, halo and alkyl; each R24 is independently selected from the group consisting of H and alkyl; each R25 is independently selected from the group consisting of H, hydroxyl, alkyl, hydroxyalkyl, aryl, cycloalkyl, heteroaryl, -NR24R24 , -(C1 to C& alkyl)NR24N24, -CF3 and -S(O)xR23;
R26 is selected from the group consisting of H, alkyl, cycloalkyl, aryl, and heteroaryl;
R27 is selected from the group consisting of H, alkyl, cycloalkyl, aryl, and heteroaryl; and each of R31 and R32 is the same or different and wherein each is independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, heteroaryl, -NR24R25, -(CH2)3NH(C=NH)NH2, -CH2C(O)NH2, -CH2C(O)OH, - CH2SH, -CH2S-SCH2CH(NH2)C(O)OH,
-CH2CH2C(O)OH, -CH2CH2C(O)NH2, -(CH2)4NH2, -CH2CH2CH(OH)CH2NH2, -CH2CH(CHs)2, -CH(CH3)CH2(CH3), -CH2CH2SCH3, -CH2OH, -CH(OH)(CH3),
Figure imgf000066_0001
or R31 and R32, together with the N to which R31 is attached and the C to which R31 is attached, form a 5-membered ring which is unsubstituted or optionally independently substituted with a hydroxyl group.
2. The compound according to claim 1 , wherein n is 1.
3. The compound according to claim 1 , wherein:
M, together with the two carbon atoms to which it is shown attached in formula (I), represents a 4-5 membered hetereocyclyl or heterocyclenyl comprising 0-1 carbonyl groups, 0-1 double bonds, and 1 heteroatom selected from O, N, and S, wherein said 4-5 membered hetereocyclyl can, in addition to the four substituents V, R2, T, and -(W)n-X-U-R1 as set forth in formula (I), be further optionally substituted with R21;
T is selected from H and -C(O)OR3;
V is -C(O)R4 or -C(O)NR24R25, W is -(C(R3)(R4))n2-;
X is aryl, wherein said aryl is unsubstituted or optionally independently substituted with one to four selected R20 moieties which can be the same or different, each R20 moiety being independently selected from the group of R20 moieties below,
U is -Y-(C(R3)(R4))q-;
Y is -O-; n is 0 to 2; n2 is 1 to 2; q is 1 to 4; x is 0 to 2;
R1 is heteroaryl, wherein said heteroaryl group of R1 is unsubstituted or optionally independently substituted with one to six R20 moieties which can be the same or different, each R20 moiety being independently selected from the group of R20 moieties below, each R2, R4 and R5 is the same or different and each is independently selected from the group consisting of H, halo, alkyl, R22-substituted alkyl, cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl, heteroaryl, -OR6, -C(O)R7, -C(O)OR6, -NR24R25, -NR24C(O)R25, -N(=C-O-NR24R25), -NR24S(O)2R25, wherein each of the cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl and heteroaryl groups of R2, R4 and R5 is unsubstituted or optionally independently substituted with one to six alkyl, R22-substituted alkyl or R22 moieties which can be the same or different, each R22 moiety being independently selected from the group of R22 moieties below; each R3 is the same or different and is independently selected from the group consisting of H, alkyl, R22-substituted alkyl, cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl, heteroaryl, -OR6, -C(O)R7, -C(O)OR6, -NR24R25, -NR24C(O)R25, -N(=C-O-NR24R25) and -NR24S(O)2R25, each of the cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl and heteroaryl groups of R3 is unsubstituted or optionally independently substituted with one to four alkyl, R22-substituted alkyl or R22 moieties which can be the same or different, each R22 moiety being independently selected from the group of R22 moieties below; each R6 is independently selected from the group consisting of H, alkyl and -OCF3; each R7 is independently selected from the group consisting of H, alkyl, heteroaryl and -CF3; each R20 is independently selected from the group consisting of: alkyl, R21- substituted alkyl, -OR3, halo, -CN, -NO2, -NR24R25, -C(O)R3, -C(O)OR3, -C(O)NR24R25, -S(O)xNR24R25, -S(O)xR5, -CF3, -OCF3, -CF2CF3, -C(=NOH)R3, aryl, heteroaryl, cycloalkyl, hetereocyclyl, -N(R25)S(O)XR5, - N(R25)C(O)R5, and -N(R25)C(O)NR24R25, wherein each of the aryl, heteroaryl, cycloalkyl and hetereocyclyl groups of R20 is unsubstituted or optionally independently substituted with one to four R22 moieties which can be the same or different, each R22 moiety being independently selected from the group of R23 moieties below, or two R20 groups taken together with the carbon to which both R20 groups
are attached
Figure imgf000068_0001
R21 is one to three substituents independently selected from the group consisting of: -OR3, halo, -CN, -NO2, -NR24R25, -C(O)R3, -C(O)OR3, -C(O)NR24R25, -S(O)xNR24R25, -SOxR5, -CF3, -OCF3, -CF2CF3, -C(=NOH)R3, R23- substituted alkyl, aryl, heteroaryl, cycloalkyl, hetereocyclyl, -N(R25)S(O)XR5, - N(R25)C(O)R5, and -N(R25)C(O)NR24R25; wherein each of the aryl, heteroaryl, cycloalkyl, and hetereocyclyl groups of R21 is unsubstituted or optionally independently substituted with one to four R23 moieties which can be the same or different, each R23 moiety being independently selected from the group of R23 moieties below, or two R21 groups taken together with the carbon to which both R21 groups
are attached
Figure imgf000068_0002
each R22 is independently selected from the group consisting of: halo, alkynyl, aryl, heteroaryl, -OR24, -(C1-C6 alkyl)-OR24, -CN, -NO2, -NR24R25, -C(O)R23, -C(O)OR23, -C(O)NR24R25, -S(O)xNR24R25, -S(O)xR23, - CF3, -OCF3, -CF2CF3, -C(=NOH)R23, -N(R24)S(O)XR25, -N(R24)C(O)R25, and N(R24)C(O)NR24R25, or two R22 groups taken together with the carbon to which both R22 groups
are attached is
Figure imgf000069_0001
each R23 is independently selected from the group consisting of H, hydroxyl, halo and alkyl; each R24 is independently selected from the group consisting of H and alkyl; each R25 is independently selected from the group consisting of H, hydroxyl, alkyl, hydroxyalkyl, aryl, cycloalkyl, heteroaryl, -NR24R24 , -(Ci to C6 alkyl)NR24N24, -CF3 and -S(O)xR23.
4. The compound according to claim 2, wherein W is -CH2-.
5. The compound according to claim 2, wherein U is -0-CH2-.
6. The compound according to claim 2, wherein U is -OCH(CO2CHa)-.
7. The compound according to claim 2, wherein T is H.
8. The compound according to claim 2, wherein T is -C(O)OCH2CH3.
9. The compound according to claim 2, wherein V is -C(O)2H.
10. The compound according to claim 2, wherein V is -C(O)NHOH.
11. The compound according to claim 2, wherein M, together with the two carbon atoms to which it is shown attached in formula (I), represents a 5 membered hetereocyclyl comprising 1 heteroatom selected from O, N, and S, wherein said 5 membered hetereocyclyl is only substituted with the four substituents V, R2, T, and -(W)n-X-U-R1 as set forth in formula (I).
12. The compound according to claim 2, wherein M, together with the two carbon atoms to which it is shown attached in formula (I), represents a 4 membered hetereocyclyl comprising 1 carbonyl group and 1 heteroatom selected from O, N, and S, wherein said 4 membered hetereocyclyl is only substituted with the four substituents V, R2, T, and -(W)n-X-U-R1 as set forth in formula (I).
13. A compound represented by the structural formula (II):
Figure imgf000070_0001
or a pharmaceutically acceptable salt, solvate or ester of said compound, wherein:
L is aryl or heteroaryl;
R1 is selected from the group consisting of alkyl, R21 -substituted alkyl, cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl, heteroaryl, -C^CR and -CR3=CR4R5, wherein each of the alkyl, cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl and heteroaryl groups of R1 is unsubstituted or optionally independently substituted with one to six R20 moieties which can be the same or different, each R20 moiety being independently selected from the group of R20 moieties below,
T is selected from the group consisting of H, alkyl, R21 -substituted alkyl, cycloalkyl, aryl, heteroaryl, hetereocyclyl, arylalkyl, heteroarylalkyl, -OR3, -C(O)R4, -C(O)OR3, -C(O)NR24R25, -C(O)NR24OR3, -C(O)SR3, -NR24R25, -NR25C(O)R4, -NR25C(O)OR3, -NR25C(O)NR24R25, -NR25C(O)NR24OR3, -SR3, -N(R24)S(O)2R25, -S(O)xNR24R25, - S(O)xNR25OR3, -CN, -P(O)(R24XOR24), -P(O)(OR24)(OR24), -C(R4)(=N(OR3)), - C(O)-N(R31)CH(R32)-C(O)NR24R25 and -C(O)N(R31)CH(R32)-C(O)-NR25OR3, wherein each of the cycloalkyl, aryl, heteroaryl, hetereocyclyl, arylalkyl and heteroarylalkyl groups of T is unsubstituted or optionally independently substituted with one to six R20 moieties which can be the same or different, each R20 moiety being independently selected from the group of R20 moieties below;
Gi is O, H, alkyl, R21 -substituted alkyl, -OR3, halo, -C(O)R3, -C(O)OR3, - C(O)NR24R25, -S(O)xNR24R25, -S(O)xR5, -CF3, -OCF3, -CF2CF3, -C(=NOH)R3, aryl, heteroaryl, cycloalkyl, hetereocyclyl, and heteroarylalkyl, wherein each of the aryl, heteroaryl, cycloalkyl, hetereocyclyl and heteroarylalkyl groups of P is unsubstituted or optionally independently substituted with one to four R23 moieties which can be the same or different, each R23 moiety being independently selected from the group of R23 moieties below,
V is selected from the group consisting of alkyl, R21 -substituted alkyl, cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl, heteroaryl, -OR3, -C(O)R4, -(CR23R24)niC(O)OR3, -C(O)NR24R25,
-(CR23R24)n1C(O)NR25OR3, -C(O)SR3, -C(R23)(R24)SH, -NR24R25, NR25C(O)R4, -NR25C(O)OR3, -NR25C(O)NR24R25, -NR25C(O)NR24OR3, -SR3, -S(O)xNR24R25, -S(O)xNR25OR3, -CN, -P(O)(R25)(OR24), -P(O)(OR24)(OR24), -C(R4X=N(OR3)), -C(O)-N(R31)CH(R32)-C(O)NR24R25 and -C(O)N(R31)CH(R32)-C(O)-NR25OR3, wherein each of the cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl and heteroaryl groups of V is unsubstituted or optionally independently substituted with one to three R20 moieties which can be the same or different, each R20 moiety being independently selected from the group of R20moieties below; n1 is O to 2; x is O to 2; each of R2, R4 and R5 is the same or different and each is independently selected from the group consisting of H, halo, alkyl, R22-substituted alkyl, cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl, heteroaryl, -OR6, -C(O)R7, -C(O)OR6, -NR24R25, -NR24C(O)R25, -N(=C-O-NR24R25), -NR24S(O)2R25, wherein each of the cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl and heteroaryl groups of R2, R4 and R5 is unsubstituted or optionally independently substituted with one to six alkyl, R22-substituted alkyl or R22 moieties which can be the same or different, each R22 moiety being independently selected from the group of R22 moieties below, or R4 and R5 taken together with the carbon to which both R4 and R5 are
attached
Figure imgf000071_0001
each R3 is the same or different and is independently selected from the group consisting of H, alkyl, R22-substituted alkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl, heteroaryl, -OR6, -C(O)R7, -C(O)OR6, -NR24R25, -NR24C(O)R25, -N(=C-O-NR24R25) and -NR24S(O)2R25, wherein each of the cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl and heteroaryl groups of R3 is unsubstituted or optionally independently substituted with one to four alkyl, R22-substituted alkyl or R22 moieties which can be the same or different, each R22 moiety being independently selected from the group of R22 moieties below; each R6 is independently selected from the group consisting of H, alkyl and -OCF3; each R7 is independently selected from the group consisting of H, alkyl, heteroaryl and -CF3; each R20 is independently selected from the group consisting of: alkyl, R21- substituted alkyl, -OR3, halo, -CN, -NO2, -NR24R25, -C(O)R3, -C(O)OR3, -C(O)NR24R25, -S(O)xNR24R25, -S(O)xR5, -CF3, -OCF3, -CF2CF3, -C(=NOH)R3, aryl, heteroaryl, cycloalkyl, hetereocyclyl, -N(R25)S(O)XR5,- N(R25)C(O)R5, and -N(R25)C(O)NR24R25, wherein each of the aryl, heteroaryl, cycloalkyl and hetereocyclyl groups of R20 is unsubstituted or optionally independently substituted with one to four R22 moieties which can be the same or different, each R22 moiety being independently selected from the group of R23 moieties below, or two R20 groups taken together with the carbon to which both R20 groups
are attached is
Figure imgf000072_0001
R21 is one to three substituents independently selected from the group consisting of: -OR3, halo, -CN, -NO2, -NR24R25, -C(O)R3, -C(O)OR3, -C(O)NR24R25, -S(O)xNR24R25, -SOxR5, -CF3, -OCF3, -CF2CF3, -C(=NOH)R3, R23- substituted alkyl, aryl, heteroaryl, cycloalkyl, hetereocyclyl, -N(R25)S(O)XR5, - N(R25)C(O)R5, and -N(R25)C(O)NR24R25; wherein each of the aryl, heteroaryl, cycloalkyl, and hetereocyclyl groups of R21 is unsubstituted or optionally independently substituted with one to four R23 moieties which can be the same or different, each R23 moiety being independently selected from the group of R23 moieties below, or two R21 groups taken together with the carbon to which both R21 groups
are attached ■ is
Figure imgf000073_0001
each R22 is independently selected from the group consisting of: halo, alkynyl, aryl, heteroaryl, -OR24, -(C1-C6 alkyl)-OR24, -CN, -NO2, -NR24R25, -C(O)R23, -C(O)OR23, -C(O)NR24R25, -S(O)xNR24R25, -S(O)xR23, - CF3, -OCF3, -CF2CF3, -C(=NOH)R23, -N(R24)S(O)XR25, -N(R24)C(O)R25, and - N(R24)C(O)NR24R25, or two R22 groups taken together with the carbon to which both R22 groups
are attached is
Figure imgf000073_0002
each R23 is independently selected from the group consisting of H, hydroxyl, halo and alkyl; each R24 is independently selected from the group consisting of H and alkyl; each R25 is independently selected from the group consisting of H, hydroxyl, alkyl, hydroxyalkyl, aryl, cycloalkyl, heteroaryl, -NR24R24 , -(Ci to C6 alkyl)NR24N24, -CF3 and -S(O)xR23; each of R31 and R32 is the same or different and wherein each is independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, heteroaryl, -NR24R25, -(CH2)3NH(C=NH)NH2,
-CH2C(O)NH2, -CH2C(O)OH, -CH2SH, -CH2S-SCH2CH(NH2)C(O)OH, -CH2CH2C(O)OH, -CH2CH2C(O)NH2, -(CH2)4NH2, -CH2CH2CH(OH)CH2NH2, -CH2CH(CHa)2, -CH(CH3)CH2(CH3), -CH2CH2SCH3, -CH2OH, -CH(OH)(CH3),
Figure imgf000074_0001
or R31 and R32, together with the N to which R31 is attached and the C to which R31 is attached, form a 5-membered ring which is unsubstituted or optionally independently substituted with a hydroxyl group.
14. The compound according to claim 13, wherein T is -C(O)OR3, wherein R3 is an alkyl.
15. The compound according to claim 13, wherein R1 is a heteroaryl with 1 heteroatom selected from S, O and N, wherein said heteroaryl is substituted with a phenyl moiety.
16. The compound according to claim 15, wherein said heteroaryl is quinolinyl.
17. The compound according to claim 13 or 16, wherein R1 is
Figure imgf000074_0002
18. The compound according to claim 13, wherein V is -(CR23R24)n1C(O)NR25OR3 wherein n1 is O, and both R3 and R25 are H.
19. The compound according to claim 13, wherein R2=R4=R5=H.
20. The compound according to claim 13, wherein L is aryl.
21. The compound according to claim 20, wherein said aryl is phenyl.
22. A compound represented by the structural formula (III):
Figure imgf000075_0001
or a pharmaceutically acceptable salt, solvate or ester of said compound, wherein:
L is aryl or heteroaryl;
R1 is selected from the group consisting of alky!, R21 -substituted alkyl, cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl, heteroaryl, -C^≡CR and -CR3=CR4R5, wherein each of the alkyl, cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl and heteroaryl groups of R1 is unsubstituted or optionally independently substituted with one to six R20 moieties which can be the same or different, each R20 moiety being independently selected from the group of R20 moieties below,
T is selected from the group consisting of H, alkyl, R21 -substituted alkyl, cycloalkyl, aryl, heteroaryl, hetereocyclyl, arylalkyl, heteroarylalkyl, -OR3, -C(O)R4, -C(O)OR3, -C(O)NR24R25, -C(O)NR24OR3, -C(O)SR3, -NR24R25, -NR25C(O)R4, - NR25C(O)OR3, -NR25C(O)NR24R25, -NR25C(O)NR24OR3, -SR3, -N(R24)S(O)2R25, - S(O)xNR24R25, -S(O)xNR25OR3, -CN, -P(O)(R24)(OR24), -P(O)(OR24)(OR24), - C(R4X=N(OR3)), -C(O)-N(R31)CH(R32)-C(O)NR24R25 and -C(O)N(R31)CH(R32)-C(O)-NR25OR3, wherein each of the cycloalkyl, aryl, heteroaryl, hetereocyclyl, arylalkyl and heteroarylalkyl groups of T is unsubstituted or optionally independently substituted with one to six R20 moieties which can be the same or different, each R20 moiety being independently selected from the group of R20 moieties below; G2 is H, alkyl, R21 -substituted alkyi, -OR3, halo, -C(O)R3, -C(O)OR3, - C(O)NR24R25, -S(O)xNR24R25, -S(O)xR5, -CF3, -OCF3, -CF2CF3, -C(=NOH)R3, aryl, heteroaryl, cycloalkyl, hetereocyclyl, and heteroarylalkyl, wherein each of the aryl, heteroaryl, cycloalkyl, hetereocyclyl and heteroarylalkyl groups of Q is unsubstituted or optionally independently substituted with one to four R23 moieties which can be the same or different, each R23 moiety being independently selected from the group of R23 moieties below,
V is selected from the group consisting of alkyl, R21-substituted alkyl, cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl, heteroaryl, -OR3, -C(O)R4, -(CR23R24)n1 C(O)OR3, -C(O)NR24R25,
-(CR23R24)niC(O)NR25OR3, -C(O)SR3, -C(R23)(R24)SH, -NR24R25, NR25C(O)R4, -NR25C(O)OR3, -NR25C(O)NR24R25, -NR25C(O)NR24OR3, -SR3, -S(O)xNR24R25, -S(O)xNR25OR3, -CN, -P(O)(R25)(OR24), -P(O)(OR24)(OR24), -C(R4X=N(OR3)), -C(O)-N(R31 )CH(R32)-C(O)NR24R25 and -C(O)N(R31)CH(R32)-C(O)-NR25OR3, wherein each of the cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl and heteroaryl groups of V is unsubstituted or optionally independently substituted with one to three R20 moieties which can be the same or different, each R20 moiety being independently selected from the group of R20moieties below; n1 is O to 2; x is O to 2; each of R2, R4 and R5 is the same or different and each is independently selected from the group consisting of H, halo, alkyl, R22-substituted alkyl, cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl, heteroaryl, -OR6, -C(O)R7, -C(O)OR6, -NR24R25, -NR24C(O)R25, -N(=C-O-NR24R25), -NR24S(O)2R25, wherein each of the cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl and heteroaryl groups of R2, R4 and R5 is unsubstituted or optionally independently substituted with one to six alkyl, R22-substituted alkyl or R22 moieties which can be the same or different, each R22 moiety being independently selected from the group of R22 moieties below, or R4 and R5 taken together with the carbon to which both R and R5 are
attached
Figure imgf000077_0001
each R3 is the same or different and is independently selected from the group consisting of H, alkyl, R22-substituted alkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl, heteroaryl, -OR6, -C(O)R7, -C(O)OR6, -NR24R25, -NR24C(O)R25, -N(=C-O-NR24R25) and -NR24S(O)2R25, wherein each of the cycloalkyl, hetereocyclyl, arylalkyl, heteroarylalkyl, aryl and heteroaryl groups of R3 is unsubstituted or optionally independently substituted with one to four alkyl, R22-substituted alkyl or R22 moieties which can be the same or different, each R22 moiety being independently selected from the group of R22 moieties below; each R6 is independently selected from the group consisting of H, alkyl and -OCF3; each R7 is independently selected from the group consisting of H, alkyl, heteroaryl and -CF3; each R20 is independently selected from the group consisting of: alkyl, R21- substituted alkyl, -OR3, halo, -CN, -NO2, -NR24R25, -C(O)R3, -C(O)OR3, -C(O)NR24R25, -S(O)xNR24R25, -S(O)xR5, -CF3, -OCF3, -CF2CF3, -C(=NOH)R3, aryl, heteroaryl, cycloalkyl, hetereocyclyl, -N(R25)S(O)XR5, - N(R25)C(O)R5, and -N(R25)C(O)NR24R25, wherein each of the aryl, heteroaryl, cycloalkyl and hetereocyclyl groups of R20 is unsubstituted or optionally independently substituted with one to four R22 moieties which can be the same or different, each R22 moiety being independently selected from the group of R23 moieties below, or two R20 groups taken together with the carbon to which both R20 groups
are attached is
Figure imgf000077_0002
R21 is one to three substituents independently selected from the group consisting of: -OR3, halo, -CN, -NO2, -NR24R25, -C(O)R3, -C(O)OR3, -C(O)NR24R25, -S(O)xNR24R25, -SOxR5, -CF3, -OCF3, -CF2CF3, -C(=NOH)R3, R23- substituted alkyl, aryl, heteroaryl, cycloalkyl, hetereocyclyl, -N(R25)S(O)XR5,- N(R25)C(O)R5, and -N(R25)C(O)NR24R25; wherein each of the aryl, heteroaryl, cycloalkyl, and hetereocyclyl groups of R21 is unsubstituted or optionally independently substituted with one to four R23 moieties which can be the same or different, each R23 moiety being independently selected from the group of R23 moieties below, or two R21 groups taken together with the carbon to which both R21 groups
axe attached
Figure imgf000078_0001
each R22 is independently selected from the group consisting of: halo, alkynyl, aryl, heteroaryl, -OR24, -(C1-C6 alkyl)-OR24, -CN, -NO2, -NR24R25, -C(O)R23, -C(O)OR23, -C(O)NR24R25, -S(O)xNR24R25, -S(O)xR23, - CF3, -OCF3, -CF2CF3, -C(=NOH)R23, -N(R24)S(O)XR25, -N(R24)C(O)R25, and - N(R24)C(O)NR24R25, or two R22 groups taken together with the carbon to which both R22 groups
are attached is
Figure imgf000078_0002
each R23 is independently selected from the group consisting of H, hydroxyl, halo and alkyl; each R24 is independently selected from the group consisting of H and alkyl; each R25 is independently selected from the group consisting of H, hydroxyl, alkyl, hydroxyalkyl, aryl, cycloalkyl, heteroaryl, -NR24R24 , -(Ci to C6 alkyl)NR24N24, -CF3 and -S(O)xR23; each of R31 and R32 is the same or different and wherein each is independently selected from the group consisting of H, alkyl, cycloalkyl, aryl, heteroaryl, -NR24R25, -(CH2)3NH(C=NH)NH2, -CH2C(O)NH2, -CH2C(O)OH, -CH2SH, -CH2S-SCH2CH(NH2)C(O)OH, -CH2CH2C(O)OH, -CH2CH2C(O)NH2, -(CH2)4NH2, -CH2CH2CH(OH)CH2NH2, -CH2CH(CH3)2, -CH(CH3)CH2(CH3), -CH2CH2SCH3, -CH2OH, -CH(OH)(CH3),
Figure imgf000079_0001
or R31 and R32, together with the N to which R31 is attached and the C to which R31 is attached, form a 5-membered ring which is unsubstituted or optionally independently substituted with a hydroxyl group.
23. The compound according to claim 22, wherein G2 is H.
24. The compound according to claim 22, wherein T is H.
25. The compound according to claim 22, wherein R2 and R5 are both hydrogen.
26. The compound according to claim 22, wherein one of R3 and R4 is H, and the other is -C(O)OR6.
27. The compound according to claim 22, wherein both R3 and R4 are H.
28. The compound according to claim 22, wherein R1 is a heteroaryl with 1 heteroatom selected from S, O and N, wherein said heteroaryl is substituted with a phenyl moiety.
29. The compound according to claim 28, wherein said heteroaryl is quinolinyl.
30. The compound according to claim 22 or 29, wherein R1 is
Figure imgf000080_0001
31. The compound according to claim 22, wherein V is selected from the group consisting of -(CR23R24)mC(O)OR3 and -(CR23R24)niC(O)NR25OR3 wherein n1 is 0 and both R3 and R25 are H.
32. The compound according to claim 22, wherein L is aryl.
33. The compound according to claim 32, wherein said aryl is phenyl.
34. A compound according to claim 1 , 2, or 3, selected from the group consisting of:
Figure imgf000080_0002
and or a pharmaceutically acceptable salt, solvate, or ester thereof.
35. A compound according to claim 1 , 13 or 22 in purified form.
36. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound according to claim 1 , 13, or 22 or a pharmaceutically acceptable salt, solvate or ester thereof, in combination with at least one pharmaceutically acceptable carrier.
37. The pharmaceutical composition of claim 36, additionally comprising an anti-inflammatory agent different from the compound according to claim 1 , 12, or 22.
38. A method for treating or preventing an inflammatory disorder comprising administering to a subject in need thereof a therapeutically effective amount of at least one compound according to claim 1 , 13, or 22 or a pharmaceutically acceptable salt, solvate, or ester thereof.
39. A method of treating a condition or disease mediated by MMPs, TNF-, aggrecanase, or a combination thereof in a subject comprising: administering to the subject in need of such treatment a therapeutically effective amount of at least one compound according to claim 1, 13, or 22 or a pharmaceutically acceptable salt, solvate, or ester thereof.
40. A method of treating a condition or disease selected from the group consisting of rheumatoid arthritis, osteoarthritis, periodontitis, gingivitis, corneal ulceration, solid tumor growth and tumor invasion by secondary metastases, neovascular glaucoma, inflammatory bowel disease, multiple sclerosis and psoriasis in a subject, comprising: administering to the subject in need of such treatment a therapeutically effective amount of at least one compound according to claim 1 , 13, or 22 or a pharmaceutically acceptable salt, solvate, or ester thereof.
41. A method of treating a condition or disease selected from the group consisting of fever, cardiovascular conditions, hemorrhage, coagulation, cachexia, anorexia, alcoholism, acute phase response, acute infection, shock, graft versus host reaction, autoimmune disease and HIV infection in a subject comprising administering to the subject in need of such treatment a therapeutically effective amount of at least one compound according to claim 1 , 13 or 22 or a pharmaceutically acceptable salt, solvate, or ester thereof.
42. A method of treating a condition or disease selected from the group consisting of septic shock, haemodynamic shock, sepsis syndrome, post ischaemic reperfusion injury, malaria, mycobacterial infection, meningitis, psoriasis, congestive heart failure, fibrotic diseases, cachexia, graft rejection, cancers such as cutaneous T-cell lymphoma, diseases involving angiogenesis, autoimmune diseases, skin inflammatory diseases, inflammatory bowel diseases such as Crohn's disease and colitis, osteo and rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, adult Still's disease, ureitis, Wegener's granulomatosis, Behcehe disease, Sjogren's syndrome, sarcoidosis, polymyositis, dermatomyositis, multiple sclerosis, radiation damage, hyperoxic alveolar injury, periodontal disease, HIV, non-insulin dependent diabetes mellitus, systemic lupus erythematosus, glaucoma, sarcoidosis, idiopathic pulmonary fibrosis, bronchopulmonary dysplasia, retinal disease, scleroderma, osteoporosis, renal ischemia, myocardial infarction, cerebral stroke, cerebral ischemia, nephritis, hepatitis, glomerulonephritis, cryptogenic fibrosing aveolitis, psoriasis, transplant rejection, atopic dermatitis, vasculitis, allergy, seasonal allergic rhinitis, reversible airway obstruction, adult respiratory distress syndrome, asthma, chronic obstructive pulmonary disease (COPD) and bronchitis in a subject comprising administering to the subject in need of such treatment a therapeutically effective amount of at least one compound according to claim 1 , 13, or 22 or a pharmaceutically acceptable salt , solvate or ester thereof.
PCT/US2006/031151 2005-08-12 2006-08-10 Compounds for the treatment of inflammatory disorders WO2007021803A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP06789659A EP1948638B1 (en) 2005-08-12 2006-08-10 Compounds for the treatment of inflammatory disorders
AT06789659T ATE518853T1 (en) 2005-08-12 2006-08-10 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES
MX2008002073A MX2008002073A (en) 2005-08-12 2006-08-10 Compounds for the treatment of inflammatory disorders.
CA002618679A CA2618679A1 (en) 2005-08-12 2006-08-11 Compounds for the treatment of inflammatory disorders
JP2008526185A JP2009504666A (en) 2005-08-12 2006-08-11 Compounds for treating inflammatory diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70765305P 2005-08-12 2005-08-12
US60/707,653 2005-08-12

Publications (2)

Publication Number Publication Date
WO2007021803A1 true WO2007021803A1 (en) 2007-02-22
WO2007021803A8 WO2007021803A8 (en) 2008-01-10

Family

ID=37560931

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/031151 WO2007021803A1 (en) 2005-08-12 2006-08-10 Compounds for the treatment of inflammatory disorders

Country Status (8)

Country Link
US (1) US7879997B2 (en)
EP (1) EP1948638B1 (en)
JP (1) JP2009504666A (en)
CN (1) CN101282962A (en)
AT (1) ATE518853T1 (en)
CA (1) CA2618679A1 (en)
MX (1) MX2008002073A (en)
WO (1) WO2007021803A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012005229A1 (en) 2010-07-08 2012-01-12 科研製薬株式会社 N-hydroxyformamide derivative and pharmaceutical containing same
US9771332B2 (en) 2015-05-05 2017-09-26 Pfizer Inc. 2-thiopyrimidinones
US9873673B2 (en) 2011-11-11 2018-01-23 Pfizer Inc. 2-thiopyrimidinones

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
EP0574758A1 (en) 1992-06-11 1993-12-22 F. Hoffmann-La Roche Ag Hydroxamic acid derivatives as collagenase inhibitors
GB2268934A (en) 1992-07-23 1994-01-26 British Bio Technology Hydroxamic acid derivatives
WO1994024140A1 (en) 1993-04-17 1994-10-27 British Bio-Technology Limited Hydroxamic acid derivatives
WO1995009841A1 (en) 1993-10-07 1995-04-13 British Biotech Pharmaceuticals Limited Hydroxamic acid derivatives as inhibitors of cytokine production
US5420298A (en) * 1992-09-01 1995-05-30 Zeneca Limited Pyrrolidine derivatives
US6114361A (en) * 1998-11-05 2000-09-05 Pfizer Inc. 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
EP1138680A1 (en) * 2000-03-29 2001-10-04 Pfizer Products Inc. Gem substituted sulfonyl hydroxamic acids as MMP inhibitors
US20020137734A1 (en) * 2001-01-11 2002-09-26 Xiao-Tao Chen 1,1-Disubstituted cyclic inhibitors of matrix metalloproteases and TNF-alpha
WO2003053940A1 (en) 2001-12-20 2003-07-03 Bristol-Myers Squibb Company Barbituric acid derivatives as inhibitors of tnf-$g(a) converting enzyme (tace) and/or matrix metalloproteinases
US6838466B2 (en) 2001-12-20 2005-01-04 Schering Corporation Compounds for the treatment of inflammatory disorders
US20050113344A1 (en) * 2003-10-17 2005-05-26 Incyte Corporation Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases
WO2005077937A1 (en) * 2004-01-09 2005-08-25 Cadila Healthcare Limited Substituted hydroxamic acid derivatives as tnf inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1099690A4 (en) 1998-07-23 2001-10-17 Shionogi & Co Monocyclic beta-lactam compounds and chymase inhibitors containing the same
EP1656368A4 (en) * 2002-07-09 2009-08-26 Bristol Myers Squibb Co Substituted hertocyclic derivatives useful as antidiabetic and antiobesity agents and method
US7638513B2 (en) * 2004-06-02 2009-12-29 Schering Corporation Compounds for the treatment of inflammatory disorders
PE20060426A1 (en) * 2004-06-02 2006-06-28 Schering Corp TARTARIC ACID DERIVATIVES AS INHIBITORS OF MMPs, ADAMs, TACE AND TNF-alpha
US7488745B2 (en) * 2004-07-16 2009-02-10 Schering Corporation Compounds for the treatment of inflammatory disorders
US7504424B2 (en) * 2004-07-16 2009-03-17 Schering Corporation Compounds for the treatment of inflammatory disorders
RU2007105685A (en) * 2004-07-16 2008-08-27 Шеринг Корпорейшн (US) GIDANTONIN DERIVATIVES FOR TREATMENT OF INFLAMMATORY DISEASES
AR059037A1 (en) * 2006-01-17 2008-03-12 Schering Corp COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
ATE540932T1 (en) * 2006-08-31 2012-01-15 Schering Corp HYDANTOIN DERIVATIVES AS ANTIBACTERIAL ACTIVE INGREDIENTS

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
EP0574758A1 (en) 1992-06-11 1993-12-22 F. Hoffmann-La Roche Ag Hydroxamic acid derivatives as collagenase inhibitors
GB2268934A (en) 1992-07-23 1994-01-26 British Bio Technology Hydroxamic acid derivatives
US5420298A (en) * 1992-09-01 1995-05-30 Zeneca Limited Pyrrolidine derivatives
WO1994024140A1 (en) 1993-04-17 1994-10-27 British Bio-Technology Limited Hydroxamic acid derivatives
WO1995009841A1 (en) 1993-10-07 1995-04-13 British Biotech Pharmaceuticals Limited Hydroxamic acid derivatives as inhibitors of cytokine production
US6114361A (en) * 1998-11-05 2000-09-05 Pfizer Inc. 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
EP1138680A1 (en) * 2000-03-29 2001-10-04 Pfizer Products Inc. Gem substituted sulfonyl hydroxamic acids as MMP inhibitors
US20020137734A1 (en) * 2001-01-11 2002-09-26 Xiao-Tao Chen 1,1-Disubstituted cyclic inhibitors of matrix metalloproteases and TNF-alpha
WO2003053940A1 (en) 2001-12-20 2003-07-03 Bristol-Myers Squibb Company Barbituric acid derivatives as inhibitors of tnf-$g(a) converting enzyme (tace) and/or matrix metalloproteinases
US6838466B2 (en) 2001-12-20 2005-01-04 Schering Corporation Compounds for the treatment of inflammatory disorders
US20050113344A1 (en) * 2003-10-17 2005-05-26 Incyte Corporation Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases
WO2005077937A1 (en) * 2004-01-09 2005-08-25 Cadila Healthcare Limited Substituted hydroxamic acid derivatives as tnf inhibitors

Non-Patent Citations (26)

* Cited by examiner, † Cited by third party
Title
"Bioreversible Carriers in Drug Design", 1987, AMERICAN PHARMACEUTICAL ASSOCIATION AND PERGAMON PRESS
"Handbook of Pharmaceutical Salts. Properties, Selection and Use", 2002, WILEY-VCH
"The Orange Book", FOOD & DRUG ADMINISTRATION
A. L. BINGHAM ET AL., CHEM. COMMUN., 2001, pages 603 - 604
ANDERSON ET AL.: "The Practice of Medicinal Chemistry", 1996, ACADEMIC PRESS
BALDWIN, J. E.; ADLINGTON, R. M.; GOILINS, D. W.; SCHOFIELD, C. J., TETRAHEDRON, vol. 46, no. 13-14, 1990, pages 4733 - 48
BISHOP, J. E.; O'CONNELL, J. F.; RAPOPORT, H., J. ORG. CHEM., vol. 56, 1991, pages 5079
BLACK R.A.: "Tumor necrosis factor-alpha converting enzyme", INT J BIOCHEM CELL BIOL., vol. 34, no. 1, January 2002 (2002-01-01), pages 1 - 5
E. C. VAN TONDER ET AL., AAPS PHARMSCITECH., vol. 5, no. 1, 2004
FELDMAN ET AL., LANCET, vol. 344, 1994, pages 1105
GEARING ET AL., NATURE, vol. 370, 1994, pages 555
JACS, vol. 123, 2001, pages 10770
LOHMANDER L. S. ET AL., ARTHRITIS RHEUM, vol. 36, 1993, pages 1214 - 22
LOHMANDER L. S. ET AL., ARTHRITIS RHEUM., vol. 36, 1993, pages 1214 - 22
M. CAIRA ET AL., J. PHARMACEUTICAL SCI., vol. 93, no. 3, 2004, pages 601 - 611
MACDONALD T. ET AL., CLIN. EXP. IMMUNOL., vol. 81, 1990, pages 301
MANKIN ET AL., ARTHRITIS RHEUM., vol. 21, 1978, pages 761 - 766
MOSS ML; WHITE JM; LAMBERT MH; ANDREWS RC.: "TACE and other ADAM proteases as targets for drug discovery", DRUG DISCOV TODAY., vol. 6, no. 8, 1 April 2001 (2001-04-01), pages 417 - 426
NIWA, Y.; SHIMIZU, M., JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 125, no. 13, 2003, pages 3720 - 3721
P. GOULD, INTERNATIONAL J. OF PHARMACEUTICS, vol. 33, 1986, pages 201 - 217
S. BERGE ET AL., JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 66, no. 1, 1977, pages 1 - 19
T. HIGUCHI; V. STELLA: "Pro-drugs as Novel Delivery Systems", A.C.S. SYMPOSIUM SERIES, vol. 14, 1987
T. HIGUCHI; W. STELLA: "Pro-drugs as Novel Delivery Systems", A.C.S. SYMPOSIUM SERIES, vol. 14
T. W. GREENE ET AL.: "Protective Groups in organic Synthesis", 1991, WILEY
WAHL ET AL., ANN. REP. MED. CHEM., vol. 25, 1990, pages 175 - 184
WOESSNER ET AL., ARTHRITIS RHEUM., vol. 26, 1983, pages 63 - 68

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012005229A1 (en) 2010-07-08 2012-01-12 科研製薬株式会社 N-hydroxyformamide derivative and pharmaceutical containing same
US9873673B2 (en) 2011-11-11 2018-01-23 Pfizer Inc. 2-thiopyrimidinones
US9771332B2 (en) 2015-05-05 2017-09-26 Pfizer Inc. 2-thiopyrimidinones

Also Published As

Publication number Publication date
MX2008002073A (en) 2008-04-16
US20070191332A1 (en) 2007-08-16
ATE518853T1 (en) 2011-08-15
CN101282962A (en) 2008-10-08
EP1948638A1 (en) 2008-07-30
EP1948638B1 (en) 2011-08-03
CA2618679A1 (en) 2007-02-22
JP2009504666A (en) 2009-02-05
WO2007021803A8 (en) 2008-01-10
US7879997B2 (en) 2011-02-01

Similar Documents

Publication Publication Date Title
US8178553B2 (en) Compounds for the treatment of inflammatory disorders
EP1778676B1 (en) Hydantoin derivatives for the treatment of inflammatory disorders
US8541572B2 (en) Compounds for the treatment of inflammatory disorders
WO2007084415A2 (en) Compounds for the treatment of inflammatory disorders
EP2331528B1 (en) Compounds for the treatment of inflammatory disorders
EP2346857B1 (en) Compounds for the treatment of inflammatory disorders
US7879997B2 (en) Compounds for the treatment of inflammatory disorders
US20090239890A1 (en) Spiro substituted cyclopropane compounds for the treatment of inflammatory disorders
MX2008009297A (en) Hydantoin compounds for the treatment of inflammatory disorders
MX2008009295A (en) Hydantoin derivatives for the treatment of inflammatory disorders

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680037119.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2618679

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008526185

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/002073

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006789659

Country of ref document: EP